{
  "$schema_version": "5.3",
  "review_mode": "fresh",
  "claim_restatement": {
    "index_wording": "Cytokine Storm as Primary Driver",
    "entry_form": "phenomenon",
    "gradeable_restatement": "Systemic hypercytokinemia at a magnitude comparable to sepsis, hyperinflammatory ARDS or CAR-T cytokine release syndrome is the primary driver of severe COVID-19 pathology and mortality.",
    "restatement_required": true,
    "split_into": [],
    "parent_claim": null,
    "scope_qualifiers": [
      {
        "qualifier": "Species, genotype, baseline disease, diet, dose and timing",
        "determinable_before_outcome": true,
        "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.",
        "action": "retained"
      }
    ]
  },
  "hypothesis": {
    "name": "Cytokine Storm as Primary Driver",
    "central_claim": "Systemic hypercytokinemia at a magnitude comparable to sepsis, hyperinflammatory ARDS or CAR-T cytokine release syndrome is the primary driver of severe COVID-19 pathology and mortality.",
    "proposed_mechanism": "Systemic hypercytokinemia at a magnitude comparable to sepsis, hyperinflammatory ARDS or CAR-T cytokine release syndrome is the primary driver of severe COVID-19 pathology and mortality.",
    "claimed_scope": "Hospitalized severe/critical COVID-19, separating baseline support, biomarker entry, symptom-to-treatment timing, vaccination and treatment eras. Evidence is dominated by 2020-2022 enrollment; later publication dates do not imply later-era populations.",
    "claimed_level": [
      "primacy",
      "generalization"
    ],
    "is_conjunctive": true,
    "conjunctive_note": "Scope-matched follows the index. SC4 gates the broad primacy claim; positive treatment contribution in SC3 is preserved separately and cannot establish SC2 magnitude or SC4 primacy."
  },
  "rubric_routing": {
    "primary_rubric": "05-immunology-inflammation.md",
    "secondary_rubrics": [],
    "index_notes_applied": [
      "Scope-matched follows the index. SC4 gates the broad primacy claim; positive treatment contribution in SC3 is preserved separately and cannot establish SC2 magnitude or SC4 primacy."
    ],
    "rubric_fit_note": "Exact archived v5.3 framework. Any stale index empirical framing is rechecked against primary results."
  },
  "subclaim_matrix": {
    "subclaims": [
      {
        "id": "SC1",
        "statement": "Circulating IL-6 is elevated in severe COVID-19 and predicts deterioration and death.",
        "subclaim_type": "existence",
        "scope": "defined hospitalized severe COVID-19 cohorts",
        "claimed_scope": "defined hospitalized severe COVID-19 cohorts",
        "governing_rubric": "05-immunology-inflammation.md",
        "key_evidence_anchor": "Time-ordered cytokine measurements and clinical outcomes",
        "hsef_level": "Β",
        "confidence": "Moderate",
        "governing_cap_or_threshold": "Quoted boundary and upward audit below.",
        "rationale": "Circulating IL6 and related markers predict deterioration and survival, including temporal validation [3-7,58]. This is a strong prognostic observation, not causal primacy."
      },
      {
        "id": "SC2",
        "statement": "Circulating cytokine elevation reaches comparator-defined storm magnitude.",
        "subclaim_type": "mechanism",
        "scope": "severe/critical COVID-19 compared with sepsis, ARDS and CAR-T CRS",
        "claimed_scope": "severe/critical COVID-19 compared with sepsis, ARDS and CAR-T CRS",
        "governing_rubric": "05-immunology-inflammation.md",
        "key_evidence_anchor": "Harmonized assays, timing, treatment and comparator sampling",
        "hsef_level": "Β",
        "confidence": "Moderate",
        "governing_cap_or_threshold": "Quoted boundary and upward audit below.",
        "rationale": "Direct comparative observations are heterogeneous. The same-method ICU comparison and influenza comparison constrain general storm magnitude [1,68]; the small MFI-panel null [2] is not equivalence. The registered magnitude claim is not established across its scope."
      },
      {
        "id": "SC3",
        "statement": "IL-6/IL-1 pathway signalling contributes causally to adverse outcomes in prespecified hospitalized populations.",
        "subclaim_type": "mechanism",
        "scope": "trial-defined hypoxaemic/inflammation-marker-positive hospitalized patients",
        "claimed_scope": "trial-defined hypoxaemic/inflammation-marker-positive hospitalized patients",
        "governing_rubric": "05-immunology-inflammation.md",
        "key_evidence_anchor": "Randomized pathway perturbation with mortality and recovery endpoints",
        "hsef_level": "Ζ",
        "confidence": "Moderate",
        "governing_cap_or_threshold": "Quoted boundary and upward audit below.",
        "rationale": "IL6R-targeted mortality/organ-support benefits in separate RECOVERY and REMAP-CAP populations, placebo-controlled composite benefit in EMPACTA, and mechanistically different IL1 perturbation in SAVE-MORE reduce a purely passive-inflammatory-marker interpretation [13-15,18]. IL6R blockade is one causal line under the framework's independence test (agents of the same modality against the same target do not count twice, and replication adds confidence rather than a line); Ζ rests on its convergence with the mechanistically distinct IL1 blockade result and the infected-model IL1beta genetic contrast. IL1 clinical contribution is more selection-sensitive and bounded at Ε. Nulls identify boundaries rather than erasing all causal contribution [16-26,29-30]."
      },
      {
        "id": "SC4",
        "statement": "Systemic hypercytokinemia is the primary driver across the severe/critical population.",
        "subclaim_type": "primacy",
        "scope": "severe/critical COVID-19, baseline setting and treatment era explicit",
        "claimed_scope": "severe/critical COVID-19, baseline setting and treatment era explicit",
        "governing_rubric": "05-immunology-inflammation.md",
        "key_evidence_anchor": "Causal comparisons with viral burden, interferon failure and immunothrombosis",
        "hsef_level": "Γ",
        "confidence": "Moderate",
        "governing_cap_or_threshold": "Quoted boundary and upward audit below.",
        "rationale": "Positive pathway-specific trials establish contribution, but cannot identify circulating magnitude or the fraction of disease primarily caused by that state. Host IFN natural experiments, antiviral benefit, vascular injury and compartment data make systemic-storm primacy mechanistically unestablished [32,37-50,54-57,68]."
      },
      {
        "id": "SC5",
        "statement": "The pathogenic cytokine action is systemic rather than primarily pulmonary-compartmental.",
        "subclaim_type": "mechanism",
        "scope": "matched blood and pulmonary samples",
        "claimed_scope": "matched blood and pulmonary samples",
        "governing_rubric": "05-immunology-inflammation.md",
        "key_evidence_anchor": "Compartment-specific measurement and perturbation",
        "hsef_level": "Γ",
        "confidence": "Moderate",
        "governing_cap_or_threshold": "Quoted boundary and upward audit below.",
        "rationale": "Systemic drug delivery does not localize pathogenic action. Paired blood/lung measurements show mediator-specific compartment relations and treatment effects, not proof that the disease-driving cytokine action is primarily systemic [11,51-54,65-67]."
      }
    ],
    "aggregation_rule": "scope-matched",
    "aggregation_preregistered": true,
    "aggregation_rationale": "Scope-matched follows the index. SC4 gates the broad primacy claim; positive treatment contribution in SC3 is preserved separately and cannot establish SC2 magnitude or SC4 primacy.",
    "primary_subclaim_id": "SC4",
    "aggregation_derivation": "The preregistered scope-matched gate SC4 yields Γ / Moderate for systemic-storm primacy. SC3 earns Ζ for convergent targeted cytokine contribution in prespecified hospitalized contexts; this is explicitly retained. Weakest-link sensitivity is Β because SC1/SC2 are descriptive observations. Primary-subclaim and scope-matched sensitivities are Γ. Treatable inflammation and a cytokine-first systemic magnitude claim are different propositions.",
    "aggregation_alternatives": {
      "weakest_link_would_return": "Β",
      "primary_subclaim_would_return": "Γ",
      "scope_matched_would_return": "Γ",
      "note": "Separate narrow successes do not replace the preregistered gate."
    },
    "index_rule_deviation": ""
  },
  "competing_models": {
    "models_evaluated": [
      {
        "rank_in_tournament": 1,
        "model_id": "M2",
        "is_nominal": false,
        "name": "Host-state and stage-dependent inflammatory contribution",
        "core_claim": "Specific inflammation contributes under defined clinical conditions rather than one universal systemic storm.",
        "explains_what_nominal_does_not": "Specific inflammation contributes under defined clinical conditions rather than one universal systemic storm.",
        "strongest_supporting_evidence": [
          "Targeted IL6R/IL1 trials and eligibility/timing/dose contrasts [13-30,36] support causal boundaries."
        ],
        "strongest_contradictory_evidence": [
          "Whole-population dominance and mediator-specific clinical prediction remain incomplete; multiple treatment contexts are null."
        ],
        "hsef_level_for_this_model": "Ε",
        "rationale": "Targeted IL6R/IL1 trials and eligibility/timing/dose contrasts [13-30,36] support causal boundaries. Whole-population dominance and mediator-specific clinical prediction remain incomplete; multiple treatment contexts are null."
      },
      {
        "rank_in_tournament": 2,
        "model_id": "M3",
        "is_nominal": false,
        "name": "Early antiviral interferon failure in susceptible hosts",
        "core_claim": "Inherited or autoimmune disruption of early IFN protection causes susceptibility before downstream inflammation.",
        "explains_what_nominal_does_not": "Inherited or autoimmune disruption of early IFN protection causes susceptibility before downstream inflammation.",
        "strongest_supporting_evidence": [
          "Human functional genetic and neutralizing-autoantibody natural experiments, preinfection samples and cellular vulnerability [43-50] reduce ordinary reverse-causation explanations."
        ],
        "strongest_contradictory_evidence": [
          "Selected genetic/autoantibody groups are not all cases; shared recruitment and comparator cohorts prevent treating every report as independent. Late IFN treatment can fail or harm [39]."
        ],
        "hsef_level_for_this_model": "Ζ",
        "rationale": "Human functional genetic and neutralizing-autoantibody natural experiments, preinfection samples and cellular vulnerability [43-50] reduce ordinary reverse-causation explanations. Selected genetic/autoantibody groups are not all cases; shared recruitment and comparator cohorts prevent treating every report as independent. Late IFN treatment can fail or harm [39]."
      },
      {
        "rank_in_tournament": 3,
        "model_id": "M4",
        "is_nominal": false,
        "name": "Endothelial and immunothrombotic injury",
        "core_claim": "Vascular and coagulation mechanisms interact with infection and inflammation.",
        "explains_what_nominal_does_not": "Vascular and coagulation mechanisms interact with infection and inflammation.",
        "strongest_supporting_evidence": [
          "Stage-specific heparin contrast [37-38], fibrin domain intervention [55] and autopsy vascular pathology [57] narrow a real contribution."
        ],
        "strongest_contradictory_evidence": [
          "Autopsy is end-stage; heparin is not all immunothrombosis and its critical-care null constrains generalized efficacy."
        ],
        "hsef_level_for_this_model": "Ε",
        "rationale": "Stage-specific heparin contrast [37-38], fibrin domain intervention [55] and autopsy vascular pathology [57] narrow a real contribution. Autopsy is end-stage; heparin is not all immunothrombosis and its critical-care null constrains generalized efficacy."
      },
      {
        "rank_in_tournament": 4,
        "model_id": "M5",
        "is_nominal": false,
        "name": "Pulmonary compartmental inflammatory injury",
        "core_claim": "Local cytokine, complement and repair abnormalities can differ from blood measurements.",
        "explains_what_nominal_does_not": "Local cytokine, complement and repair abnormalities can differ from blood measurements.",
        "strongest_supporting_evidence": [
          "Paired blood/BAL and epithelial circuit studies [11,54,62,65-67] support local mechanism plausibility."
        ],
        "strongest_contradictory_evidence": [
          "No examined human compartment-restricted hard-outcome test establishes pulmonary primacy; raw BAL dilution and treatment matter."
        ],
        "hsef_level_for_this_model": "Γ",
        "rationale": "Paired blood/BAL and epithelial circuit studies [11,54,62,65-67] support local mechanism plausibility. No examined human compartment-restricted hard-outcome test establishes pulmonary primacy; raw BAL dilution and treatment matter."
      },
      {
        "rank_in_tournament": 5,
        "model_id": "M1",
        "is_nominal": true,
        "name": "Systemic cytokine-storm primacy",
        "core_claim": "Comparator-magnitude circulating cytokines dominate severe COVID pathology and mortality.",
        "explains_what_nominal_does_not": "Comparator-magnitude circulating cytokines dominate severe COVID pathology and mortality.",
        "strongest_supporting_evidence": [
          "Prediction and positive cytokine-directed interventions support an inflammatory component [5-7,13-15,18]."
        ],
        "strongest_contradictory_evidence": [
          "Comparator magnitude, trial nulls and susceptibility/compartment alternatives block universal primacy [1-2,16-30,43-50,54,68]."
        ],
        "hsef_level_for_this_model": "Γ",
        "rationale": "Prediction and positive cytokine-directed interventions support an inflammatory component [5-7,13-15,18]. Comparator magnitude, trial nulls and susceptibility/compartment alternatives block universal primacy [1-2,16-30,43-50,54,68]."
      }
    ],
    "tournament_summary": "Descriptive comparison; does not modify the nominal score. Targeted IL6R benefit versus cytokine-level prediction distinguishes causal contribution from prognostic inflammation. Human inherited and neutralizing-autoantibody IFN defects distinguish a temporally upstream susceptibility pathway from the broad systemic-storm account, while leaving inflammatory amplification compatible.",
    "study_separating_rank1_from_rank2": "Targeted IL6R benefit versus cytokine-level prediction distinguishes causal contribution from prognostic inflammation. Human inherited and neutralizing-autoantibody IFN defects distinguish a temporally upstream susceptibility pathway from the broad systemic-storm account, while leaving inflammatory amplification compatible.",
    "nominal_wins_only_by_funding_artifact": false,
    "level_unchanged_by_tournament": true
  },
  "evidence_inventory": [
    {
      "n": 1,
      "pmid": "32880615",
      "title": "Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions.",
      "citation": "Kox M, Waalders NJB, Kooistra EJ et al. Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions. JAMA. 2020.",
      "doi": "10.1001/jama.2020.17052",
      "pmcid": "PMC7489366",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32880615/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32880615/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32880615",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: Publisher Methods, Results and Discussion, displayed lines 141-196; summary receipt. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "negative",
      "what_it_shows": "Same-method ICU comparison found lower circulating IL6 in COVID ARDS than septic-shock ARDS.",
      "what_it_does_not_show": "Historical cohorts, timing, disease severity and unmeasured assay-lot variability constrain magnitude inference.",
      "confounders_present": [
        "Historical cohorts, timing, disease severity and unmeasured assay-lot variability constrain magnitude inference."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 2,
      "pmid": "32706339",
      "title": "Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.",
      "citation": "Wilson JG, Simpson LJ, Ferreira AM et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI insight. 2020.",
      "doi": "10.1172/jci.insight.140289",
      "pmcid": "PMC7526438",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32706339/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32706339/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32706339",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph1, 1:Results:paragraph2, 1:Results:paragraph3, 2:Discussion:paragraph0, 2:Discussion:paragraph1, 2:Discussion:paragraph3, 2:Discussion:paragraph4, 3:Methods:paragraph1, 3:Methods:paragraph2, 3:Methods:paragraph3, 3:Methods:paragraph4, 3:Methods:paragraph5. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Small same-panel comparison detected no significant cytokine differences between COVID, ARDS and sepsis.",
      "what_it_does_not_show": "Luminex MFI cannot be converted to comparable pg/mL; low power and nonsignificance do not establish equivalence.",
      "confounders_present": [
        "Luminex MFI cannot be converted to comparable pg/mL; low power and nonsignificance do not establish equivalence."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 3,
      "pmid": "33348065",
      "title": "Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients.",
      "citation": "Bülow Anderberg S, Luther T, Berglund M et al. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine. 2021.",
      "doi": "10.1016/j.cyto.2020.155389",
      "pmcid": "PMC7833204",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33348065/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33348065/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33348065",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "positive",
      "what_it_shows": "Moderate cytokine increases in 24 ICU patients correlated with respiratory and kidney failure; IL8 had the strongest mortality signal.",
      "what_it_does_not_show": "Surgical controls do not test magnitude against matched sepsis; correlation does not establish primacy.",
      "confounders_present": [
        "Surgical controls do not test magnitude against matched sepsis; correlation does not establish primacy."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 4,
      "pmid": "33894209",
      "title": "Distinct cytokine profiles associated with COVID-19 severity and mortality.",
      "citation": "Dorgham K, Quentric P, Gökkaya M et al. Distinct cytokine profiles associated with COVID-19 severity and mortality. The Journal of allergy and clinical immunology. 2021.",
      "doi": "10.1016/j.jaci.2021.03.047",
      "pmcid": "PMC8061091",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33894209/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33894209/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33894209",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Admission profiles predicted mortality differently by respiratory-support category, with a validation cohort.",
      "what_it_does_not_show": "Prognostic profiles and antigen associations do not identify a universal cytokine-first cause.",
      "confounders_present": [
        "Prognostic profiles and antigen associations do not identify a universal cytokine-first cause."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 5,
      "pmid": "32839624",
      "title": "An inflammatory cytokine signature predicts COVID-19 severity and survival.",
      "citation": "Del Valle DM, Kim-Schulze S, Huang HH et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature medicine. 2020.",
      "doi": "10.1038/s41591-020-1051-9",
      "pmcid": "PMC7869028",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32839624/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32839624/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "UpdateOf: PMID32511562"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32839624",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "positive",
      "what_it_shows": "Admission IL6 and TNF predicted severity and death after adjustment in 1484 patients and a second cohort.",
      "what_it_does_not_show": "Adjusted prediction is not randomized causal attribution; index inflammatory framing is not accepted as a result.",
      "confounders_present": [
        "Adjusted prediction is not randomized causal attribution; index inflammatory framing is not accepted as a result."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 6,
      "pmid": "32425269",
      "title": "Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.",
      "citation": "Herold T, Jurinovic V, Arnreich C et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. The Journal of allergy and clinical immunology. 2020.",
      "doi": "10.1016/j.jaci.2020.05.008",
      "pmcid": "PMC7233239",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32425269/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32425269/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32425269",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "positive",
      "what_it_shows": "Peak IL6 and CRP before intubation predicted respiratory failure in development and temporal validation cohorts.",
      "what_it_does_not_show": "Peak measurements are time-varying risk markers; cutoffs are not storm definitions or proof of causality.",
      "confounders_present": [
        "Peak measurements are time-varying risk markers; cutoffs are not storm definitions or proof of causality."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 7,
      "pmid": "32717743",
      "title": "Longitudinal analyses reveal immunological misfiring in severe COVID-19.",
      "citation": "Lucas C, Wong P, Klein J et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020.",
      "doi": "10.1038/s41586-020-2588-y",
      "pmcid": "PMC7477538",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32717743/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32717743/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32717743",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "positive",
      "what_it_shows": "Serial immune profiles in 113 patients linked early cytokines and sustained maladapted responses to severe trajectories.",
      "what_it_does_not_show": "Associations can reflect viral burden and tissue injury; no pathway-specific intervention.",
      "confounders_present": [
        "Associations can reflect viral burden and tissue injury; no pathway-specific intervention."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 8,
      "pmid": "32687484",
      "title": "Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.",
      "citation": "Remy KE, Mazer M, Striker DA et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI insight. 2020.",
      "doi": "10.1172/jci.insight.140329",
      "pmcid": "PMC7526441",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32687484/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32687484/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32687484",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "negative",
      "what_it_shows": "COVID leukocytes had impaired stimulated IFNgamma/TNF production relative to critical controls; ex vivo IL7 restored T-cell output.",
      "what_it_does_not_show": "Ex vivo functional suppression can coexist with local inflammation; no in vivo IL7 outcome test.",
      "confounders_present": [
        "Ex vivo functional suppression can coexist with local inflammation; no in vivo IL7 outcome test."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 9,
      "pmid": "34956225",
      "title": "Overlapping but Disparate Inflammatory and Immunosuppressive Responses to SARS-CoV-2 and Bacterial Sepsis: An Immunological Time Course Analysis.",
      "citation": "Loftus TJ, Ungaro R, Dirain M et al. Overlapping but Disparate Inflammatory and Immunosuppressive Responses to SARS-CoV-2 and Bacterial Sepsis: An Immunological Time Course Analysis. Frontiers in immunology. 2021.",
      "doi": "10.3389/fimmu.2021.792448",
      "pmcid": "PMC8696010",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34956225/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34956225/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34956225",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "COVID and bacterial sepsis differed in early inflammation and longitudinal immune suppression over 21 days.",
      "what_it_does_not_show": "Small cohorts, treatment and timing confounding; no dominant causal pathway attribution.",
      "confounders_present": [
        "Small cohorts, treatment and timing confounding; no dominant causal pathway attribution."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 10,
      "pmid": "33524124",
      "title": "Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19.",
      "citation": "Janssen NAF, Grondman I, de Nooijer AH et al. Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. The Journal of infectious diseases. 2021.",
      "doi": "10.1093/infdis/jiab065",
      "pmcid": "PMC7928798",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33524124/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33524124/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33524124",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Innate hyperresponsiveness and adaptive dysfunction coexisted in 147 patients; clustering found no specific endotypes.",
      "what_it_does_not_show": "Functional blood assays do not establish systemic primacy or exclude tissue-specific endotypes.",
      "confounders_present": [
        "Functional blood assays do not establish systemic primacy or exclude tissue-specific endotypes."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 11,
      "pmid": "34348975",
      "title": "Comprehensive Immunologic Evaluation of Bronchoalveolar Lavage Samples from Human Patients with Moderate and Severe Seasonal Influenza and Severe COVID-19.",
      "citation": "Reynolds D, Vazquez Guillamet C, Day A et al. Comprehensive Immunologic Evaluation of Bronchoalveolar Lavage Samples from Human Patients with Moderate and Severe Seasonal Influenza and Severe COVID-19. Journal of immunology (Baltimore, Md. : 1950). 2021.",
      "doi": "10.4049/jimmunol.2100294",
      "pmcid": "PMC8387368",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34348975/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34348975/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34348975",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC5",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "negative",
      "what_it_shows": "Matched blood/BAL study found lower-airway cytokine elevations in severe viral disease; only IP10 correlated between compartments.",
      "what_it_does_not_show": "Sampling and lavage dilution limit absolute comparisons; compartment association is not compartment-specific causality.",
      "confounders_present": [
        "Sampling and lavage dilution limit absolute comparisons; compartment association is not compartment-specific causality."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 12,
      "pmid": "34051147",
      "title": "Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia.",
      "citation": "Kreutmair S, Unger S, Núñez NG et al. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. Immunity. 2021.",
      "doi": "10.1016/j.immuni.2021.05.002",
      "pmcid": "PMC8106882",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34051147/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34051147/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "ErratumIn: PMID35139354"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34051147",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Longitudinal critical-pneumonia comparison distinguished COVID exhaustion and immune-recognition signatures from shared myelopoiesis.",
      "what_it_does_not_show": "Predicted HLA binding and profiling are associative; linked erratum details remain unaudited.",
      "confounders_present": [
        "Predicted HLA binding and profiling are associative; linked erratum details remain unaudited."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 13,
      "pmid": "33933206",
      "title": "Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.",
      "citation": "  et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England). 2021.",
      "doi": "10.1016/S0140-6736(21)00676-0",
      "pmcid": "PMC8084355",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33933206/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33933206/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33933206",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph6, 1:Methods:paragraph7, 1:Methods:paragraph8, 1:Methods:paragraph9, 1:Methods:paragraph11, 1:Methods:paragraph12, 2:Results:paragraph0, 2:Results:paragraph2, 2:Results:paragraph9, 2:Results:paragraph10, 2:Results:paragraph11, 2:Results:paragraph13, 2:Results:paragraph14, 2:Results:paragraph15, 2:Results:paragraph16. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "RECOVERY tocilizumab reduced primary 28-day ITT mortality in hypoxic CRP-at-least-75 patients, 31% versus 35%, RR0.85.",
      "what_it_does_not_show": "Open label; 82% on steroids; effect identifies IL6R contribution, not circulating concentration, compartment or primary cause.",
      "confounders_present": [
        "Open label; 82% on steroids; effect identifies IL6R contribution, not circulating concentration, compartment or primary cause."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 14,
      "pmid": "33631065",
      "title": "Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.",
      "citation": " , Gordon AC, Mouncey PR et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The New England journal of medicine. 2021.",
      "doi": "10.1056/NEJMoa2100433",
      "pmcid": "PMC7953461",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33631065/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33631065/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "REMAP-CAP-IL6-domain-2020-2021",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "REMAP-CAP IL6R blockade improved organ-support-free days and survival within 24h of ICU organ support.",
      "what_it_does_not_show": "Adaptive open-label platform and concomitant treatments; initial sarilumab arm small; does not identify systemic magnitude or primacy.",
      "confounders_present": [
        "Adaptive open-label platform and concomitant treatments; initial sarilumab arm small; does not identify systemic magnitude or primacy."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 15,
      "pmid": "33332779",
      "title": "Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.",
      "citation": "Salama C, Han J, Yau L et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. The New England journal of medicine. 2021.",
      "doi": "10.1056/NEJMoa2030340",
      "pmcid": "PMC7781101",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33332779/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33332779/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33332779",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "EMPACTA reduced ventilation-or-death composite in nonventilated hospitalized patients.",
      "what_it_does_not_show": "Mortality alone did not improve; composite benefit must not be called survival benefit.",
      "confounders_present": [
        "Mortality alone did not improve; composite benefit must not be called survival benefit."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 16,
      "pmid": "33631066",
      "title": "Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.",
      "citation": "Rosas IO, Bräu N, Waters M et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. The New England journal of medicine. 2021.",
      "doi": "10.1056/NEJMoa2028700",
      "pmcid": "PMC7953459",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33631066/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33631066/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "COVACTA-NCT04320615",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "COVACTA placebo-controlled tocilizumab trial was null for primary day28 clinical status and mortality.",
      "what_it_does_not_show": "Different eligibility and treatment background from RECOVERY; confidence intervals do not exclude all context-specific effects.",
      "confounders_present": [
        "Different eligibility and treatment background from RECOVERY; confidence intervals do not exclude all context-specific effects."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 17,
      "pmid": "33085857",
      "title": "Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.",
      "citation": "Stone JH, Frigault MJ, Serling-Boyd NJ et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. The New England journal of medicine. 2020.",
      "doi": "10.1056/NEJMoa2028836",
      "pmcid": "PMC7646626",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33085857/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33085857/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33085857",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "BACC trial found no significant prevention of intubation or death with tocilizumab in moderately ill nonventilated patients.",
      "what_it_does_not_show": "Wide intervals, small trial and early treatment era; not proof IL6 never contributes.",
      "confounders_present": [
        "Wide intervals, small trial and early treatment era; not proof IL6 never contributes."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 18,
      "pmid": "34480127",
      "title": "Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.",
      "citation": "Kyriazopoulou E, Poulakou G, Milionis H et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature medicine. 2021.",
      "doi": "10.1038/s41591-021-01499-z",
      "pmcid": "PMC8516650",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34480127/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34480127/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "ErratumIn: PMID34625750"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "SAVE-MORE-NCT04680949",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph6, 1:Results:paragraph7, 1:Results:paragraph8, 1:Results:paragraph12, 1:Results:paragraph14, 1:Results:paragraph15, 2:Discussion:paragraph5, 2:Discussion:paragraph6, 3:Methods:paragraph0, 3:Methods:paragraph2, 3:Methods:paragraph3, 3:Methods:paragraph4, 3:Methods:paragraph6, 3:Methods:paragraph7. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "SAVE-MORE improved primary WHO-CPS with anakinra in suPAR-at-least-6 patients; mortality was lower in a separate survival analysis.",
      "what_it_does_not_show": "Excluded P/F below150 and NIV/MV; 85.9% on dexamethasone; WHO endpoint hierarchy differs from mortality-primary trials; linked correction not fully audited.",
      "confounders_present": [
        "Excluded P/F below150 and NIV/MV; 85.9% on dexamethasone; WHO endpoint hierarchy differs from mortality-primary trials; linked correction not fully audited."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 19,
      "pmid": "33493450",
      "title": "Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.",
      "citation": "  et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. The Lancet. Respiratory medicine. 2021.",
      "doi": "10.1016/S2213-2600(20)30556-7",
      "pmcid": "PMC7825875",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33493450/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33493450/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33493450",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "CORIMUNO-ANA-1 found no benefit on coprimary ventilation/death outcomes with anakinra.",
      "what_it_does_not_show": "Early stopped small open-label trial with different CRP eligibility and treatment era from SAVE-MORE.",
      "confounders_present": [
        "Early stopped small open-label trial with different CRP eligibility and treatment era from SAVE-MORE."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 20,
      "pmid": "34283183",
      "title": "Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.",
      "citation": "Caricchio R, Abbate A, Gordeev I et al. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021.",
      "doi": "10.1001/jama.2021.9508",
      "pmcid": "PMC8293025",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34283183/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34283183/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34283183",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "CAN-COVID canakinumab did not significantly improve survival without invasive ventilation.",
      "what_it_does_not_show": "Targets IL1beta rather than both IL1alpha/beta; a null does not establish pathway equivalence or universal absence.",
      "confounders_present": [
        "Targets IL1beta rather than both IL1alpha/beta; a null does not establish pathway equivalence or universal absence."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 21,
      "pmid": "33676590",
      "title": "Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.",
      "citation": "Lescure FX, Honda H, Fowler RA et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Respiratory medicine. 2021.",
      "doi": "10.1016/S2213-2600(21)00099-0",
      "pmcid": "PMC8078879",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33676590/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33676590/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33676590",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "Blinded multinational sarilumab trial did not improve primary clinical improvement or day29 survival.",
      "what_it_does_not_show": "Numerical critical-subgroup survival difference was not significant; exploratory subsets cannot define the claim.",
      "confounders_present": [
        "Numerical critical-subgroup survival difference was not significant; exploratory subsets cannot define the claim."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 22,
      "pmid": "35219277",
      "title": "Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.",
      "citation": "Sivapalasingam S, Lederer DJ, Bhore R et al. Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022.",
      "doi": "10.1093/cid/ciac153",
      "pmcid": "PMC8903479",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35219277/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35219277/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35219277",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "Adaptive sarilumab phase2/3 trial missed its primary endpoint; pooled post hoc steroid subgroup suggested benefit.",
      "what_it_does_not_show": "Post hoc subgroup and low steroid background in primary ventilated population limit causal subgroup claims.",
      "confounders_present": [
        "Post hoc subgroup and low steroid background in primary ventilated population limit causal subgroup claims."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 23,
      "pmid": "34902262",
      "title": "Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial.",
      "citation": "Merchante N, Cárcel S, Garrido-Gracia JC et al. Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial. Antimicrobial agents and chemotherapy. 2022.",
      "doi": "10.1128/AAC.02107-21",
      "pmcid": "PMC8846457",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34902262/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34902262/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34902262",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "SARICOR400 showed a nonsignificant trend toward less respiratory progression in inflammatory pneumonia.",
      "what_it_does_not_show": "Phase2 open-label sample115; trend and zero deaths in one arm are not confirmatory efficacy.",
      "confounders_present": [
        "Phase2 open-label sample115; trend and zero deaths in one arm are not confirmatory efficacy."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 24,
      "pmid": "37027155",
      "title": "Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.",
      "citation": "Fanlo P, Gracia-Tello BDC, Fonseca Aizpuru E et al. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial. JAMA network open. 2023.",
      "doi": "10.1001/jamanetworkopen.2023.7243",
      "pmcid": "PMC10082404",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37027155/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37027155/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID37027155",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "ANA-COVID-GEAS did not prevent mechanical ventilation or reduce mortality with anakinra.",
      "what_it_does_not_show": "Open label; selected severe hyperinflammatory population differs from suPAR selection; no universal pathway falsification.",
      "confounders_present": [
        "Open label; selected severe hyperinflammatory population differs from suPAR selection; no universal pathway falsification."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 25,
      "pmid": "34756178",
      "title": "Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.",
      "citation": "Declercq J, Van Damme KFA, De Leeuw E et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. The Lancet. Respiratory medicine. 2021.",
      "doi": "10.1016/S2213-2600(21)00377-5",
      "pmcid": "PMC8555973",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34756178/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34756178/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34756178",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "COV-AID factorial IL1/IL6 strategies did not shorten primary clinical-improvement time or show a mortality difference.",
      "what_it_does_not_show": "Low baseline mortality, serum entry criteria and factorial dosing contexts constrain scope.",
      "confounders_present": [
        "Low baseline mortality, serum entry criteria and factorial dosing contexts constrain scope."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 26,
      "pmid": "35925914",
      "title": "Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.",
      "citation": "Audemard-Verger A, Le Gouge A, Pestre V et al. Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial. PloS one. 2022.",
      "doi": "10.1371/journal.pone.0269065",
      "pmcid": "PMC9351999",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35925914/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35925914/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35925914",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "Small anakinra trial stopped early and showed worse day14 treatment success than optimized care.",
      "what_it_does_not_show": "Only71 of planned240; safety signal and uncertainty must be retained rather than generalized to all anakinra settings.",
      "confounders_present": [
        "Only71 of planned240; safety signal and uncertainty must be retained rather than generalized to all anakinra settings."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 27,
      "pmid": "38475786",
      "title": "Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial.",
      "citation": "Kyriazopoulou E, Hasin-Brumshtein Y, Midic U et al. Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial. Critical care (London, England). 2024.",
      "doi": "10.1186/s13054-024-04852-z",
      "pmcid": "PMC10935809",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38475786/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38475786/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "SAVE-MORE-NCT04680949",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "SAVE-MORE transcriptomic substudy associated anakinra with endotype transitions and respiratory-failure protection.",
      "what_it_does_not_show": "Same trial family as primary SAVE-MORE; post-treatment endotype differences are not independently randomized mediators.",
      "confounders_present": [
        "Same trial family as primary SAVE-MORE; post-treatment endotype differences are not independently randomized mediators."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 28,
      "pmid": "34612846",
      "title": "Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.",
      "citation": "Tom J, Bao M, Tsai L et al. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. Critical care medicine. 2022.",
      "doi": "10.1097/CCM.0000000000005229",
      "pmcid": "PMC8855771",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34612846/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34612846/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "ErratumIn: PMID37439653"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "COVACTA-NCT04320615",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "COVACTA exploratory biomarkers were prognostic; ferritin interactions suggested treatment-effect prediction.",
      "what_it_does_not_show": "Same COVACTA family; exploratory interactions and linked erratum not independent efficacy replication.",
      "confounders_present": [
        "Same COVACTA family; exploratory interactions and linked erratum not independent efficacy replication."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 29,
      "pmid": "34609549",
      "title": "Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial.",
      "citation": "Rosas IO, Diaz G, Gottlieb RL et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive care medicine. 2021.",
      "doi": "10.1007/s00134-021-06507-x",
      "pmcid": "PMC8490137",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34609549/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34609549/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34609549",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "REMDACTA tocilizumab plus remdesivir did not improve primary discharge time, with 88.2% receiving steroids.",
      "what_it_does_not_show": "Steroid use alone cannot explain every IL6 null; trial was not a mortality-primary precision test.",
      "confounders_present": [
        "Steroid use alone cannot explain every IL6 null; trial was not a mortality-primary precision test."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 30,
      "pmid": "40360262",
      "title": "Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial.",
      "citation": "Derde L, Gordon AC, Mouncey PR et al. Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial. Thorax. 2025.",
      "doi": "10.1136/thorax-2024-222488",
      "pmcid": "PMC12322455",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40360262/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40360262/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "REMAP-CAP-IL6-domain-2020-2021",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "Expanded REMAP-CAP cohort supported equivalent IL6R agents and a null anakinra effect in critical patients.",
      "what_it_does_not_show": "2025 publication enrolled March2020-April2021 and extends the original domain; not a fresh 2025 population replication.",
      "confounders_present": [
        "2025 publication enrolled March2020-April2021 and extends the original domain; not a fresh 2025 population replication."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 31,
      "pmid": "32678530",
      "title": "Dexamethasone in Hospitalized Patients with Covid-19.",
      "citation": " , Horby P, Lim WS et al. Dexamethasone in Hospitalized Patients with Covid-19. The New England journal of medicine. 2021.",
      "doi": "10.1056/NEJMoa2021436",
      "pmcid": "PMC7383595",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32678530/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32678530/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32678530",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "RECOVERY low-dose dexamethasone reduced mortality on oxygen or ventilation, without benefit in no-oxygen patients.",
      "what_it_does_not_show": "Pleiotropic steroid effects do not isolate a cytokine; same platform can share co-randomized patients and controls.",
      "confounders_present": [
        "Pleiotropic steroid effects do not isolate a cytokine; same platform can share co-randomized patients and controls."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 32,
      "pmid": "32445440",
      "title": "Remdesivir for the Treatment of Covid-19 - Final Report.",
      "citation": "Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 - Final Report. The New England journal of medicine. 2020.",
      "doi": "10.1056/NEJMoa2007764",
      "pmcid": "PMC7262788",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32445440/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32445440/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "ACTT1-NCT04280705",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "ACTT1 remdesivir improved primary recovery time versus placebo.",
      "what_it_does_not_show": "Mortality CI included no effect; antiviral efficacy does not quantify the fraction of death driven by virus versus inflammation.",
      "confounders_present": [
        "Mortality CI included no effect; antiviral efficacy does not quantify the fraction of death driven by virus versus inflammation."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 33,
      "pmid": "33306283",
      "title": "Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.",
      "citation": "Kalil AC, Patterson TF, Mehta AK et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. The New England journal of medicine. 2021.",
      "doi": "10.1056/NEJMoa2031994",
      "pmcid": "PMC7745180",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33306283/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33306283/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33306283",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "ACTT2 baricitinib plus remdesivir accelerated recovery versus remdesivir.",
      "what_it_does_not_show": "Mortality interval included null; JAK1/2 affects several pathways and cannot identify one circulating cytokine.",
      "confounders_present": [
        "Mortality interval included null; JAK1/2 affects several pathways and cannot identify one circulating cytokine."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 34,
      "pmid": "34480861",
      "title": "Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.",
      "citation": "Marconi VC, Ramanan AV, de Bono S et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. The Lancet. Respiratory medicine. 2021.",
      "doi": "10.1016/S2213-2600(21)00331-3",
      "pmcid": "PMC8409066",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34480861/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34480861/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "ErratumIn: PMID34508656"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34480861",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph7, 1:Methods:paragraph8, 1:Methods:paragraph9, 1:Methods:paragraph10, 1:Methods:paragraph11, 2:Results:paragraph11, 2:Results:paragraph12, 2:Results:paragraph13, 2:Results:paragraph18, 2:Results:paragraph19, 2:Results:paragraph20, 2:Results:paragraph21. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "COV-BARRIER missed primary progression endpoint but showed nominal secondary mortality reduction.",
      "what_it_does_not_show": "Failed hierarchy makes mortality p-values non-multiplicity-controlled; original Methods and Results explicitly confirm this.",
      "confounders_present": [
        "Failed hierarchy makes mortality p-values non-multiplicity-controlled; original Methods and Results explicitly confirm this."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 35,
      "pmid": "35908569",
      "title": "Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.",
      "citation": "  et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet (London, England). 2022.",
      "doi": "10.1016/S0140-6736(22)01109-6",
      "pmcid": "PMC9333998",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35908569/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35908569/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "ErratumIn: PMID36183728"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35908569",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "RECOVERY baricitinib reduced primary ITT mortality, RR0.87, on extensive steroid background.",
      "what_it_does_not_show": "JAK blockade is broader than IL6R blockade; concurrent tocilizumab and shared platform complicate line-counting.",
      "confounders_present": [
        "JAK blockade is broader than IL6R blockade; concurrent tocilizumab and shared platform complicate line-counting."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 36,
      "pmid": "37060915",
      "title": "Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.",
      "citation": " ,   et al. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England). 2023.",
      "doi": "10.1016/S0140-6736(23)00510-X",
      "pmcid": "PMC10156147",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37060915/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37060915/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID37060915",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "Higher-dose dexamethasone increased mortality versus usual low-dose care in no/simple-oxygen patients.",
      "what_it_does_not_show": "Dose and baseline support are prespecified boundaries; harm does not negate low-dose benefit in other contexts.",
      "confounders_present": [
        "Dose and baseline support are prespecified boundaries; harm does not negate low-dose benefit in other contexts."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 37,
      "pmid": "34351722",
      "title": "Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.",
      "citation": " ,  ,   et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. The New England journal of medicine. 2021.",
      "doi": "10.1056/NEJMoa2103417",
      "pmcid": "PMC8362592",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34351722/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34351722/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34351722",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "Therapeutic heparin was futile for organ-support-free days in critical COVID.",
      "what_it_does_not_show": "Therapeutic anticoagulation is not all immunothrombosis; late irreversible injury and bleeding constrain inference.",
      "confounders_present": [
        "Therapeutic anticoagulation is not all immunothrombosis; late irreversible injury and bleeding constrain inference."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 38,
      "pmid": "34351721",
      "title": "Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.",
      "citation": " ,  ,   et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. The New England journal of medicine. 2021.",
      "doi": "10.1056/NEJMoa2105911",
      "pmcid": "PMC8362594",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34351721/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34351721/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34351721",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "Therapeutic heparin improved survival-to-discharge without organ support in noncritical hospitalized patients.",
      "what_it_does_not_show": "Bleeding increased; anticoagulant and other heparin actions do not isolate systemic cytokine primacy.",
      "confounders_present": [
        "Bleeding increased; anticoagulant and other heparin actions do not isolate systemic cytokine primacy."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 39,
      "pmid": "34672949",
      "title": "Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.",
      "citation": "Kalil AC, Mehta AK, Patterson TF et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. The Lancet. Respiratory medicine. 2021.",
      "doi": "10.1016/S2213-2600(21)00384-2",
      "pmcid": "PMC8523116",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34672949/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34672949/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34672949",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "ACTT3 late IFNbeta plus remdesivir did not improve recovery and high-flow patients had worse outcomes.",
      "what_it_does_not_show": "Treatment after symptoms does not falsify inherited early IFN protection; timing and molecule matter.",
      "confounders_present": [
        "Treatment after symptoms does not falsify inherited early IFN protection; timing and molecule matter."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 40,
      "pmid": "35617986",
      "title": "Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.",
      "citation": "Wolfe CR, Tomashek KM, Patterson TF et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. The Lancet. Respiratory medicine. 2022.",
      "doi": "10.1016/S2213-2600(22)00088-1",
      "pmcid": "PMC9126560",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35617986/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35617986/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35617986",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "ACTT4 found similar ventilation-free survival with baricitinib versus dexamethasone, both plus remdesivir.",
      "what_it_does_not_show": "Active comparator, no untreated control; nonsignificance does not prove mechanistic equivalence.",
      "confounders_present": [
        "Active comparator, no untreated control; nonsignificance does not prove mechanistic equivalence."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 41,
      "pmid": "35817072",
      "title": "Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.",
      "citation": "  et al. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. The Lancet. Respiratory medicine. 2022.",
      "doi": "10.1016/S2213-2600(22)00215-6",
      "pmcid": "PMC9270059",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35817072/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35817072/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "ErratumIn: PMID36356600"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35817072",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "Hospitalized tixagevimab/cilgavimab trial missed primary sustained recovery; secondary mortality was lower.",
      "what_it_does_not_show": "Primary null, background remdesivir and variant-specific antibody activity limit broad viral-primacy conclusions; correction retained.",
      "confounders_present": [
        "Primary null, background remdesivir and variant-specific antibody activity limit broad viral-primacy conclusions; correction retained."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 42,
      "pmid": "38657001",
      "title": "SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.",
      "citation": "Singh K, Rubenstein K, Callier V et al. SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. The Journal of infectious diseases. 2024.",
      "doi": "10.1093/infdis/jiae198",
      "pmcid": "PMC11420797",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38657001/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38657001/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "ACTT1-NCT04280705",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "ACTT1 substudy linked blood viral markers, remdesivir clearance effects and clinical benefit.",
      "what_it_does_not_show": "Same ACTT1 family; biomarker mediation was not itself randomized and respiratory/blood measures differed.",
      "confounders_present": [
        "Same ACTT1 family; biomarker mediation was not itself randomized and respiratory/blood measures differed."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 43,
      "pmid": "32972996",
      "title": "Autoantibodies against type I IFNs in patients with life-threatening COVID-19.",
      "citation": "Bastard P, Rosen LB, Zhang Q et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (New York, N.Y.). 2020.",
      "doi": "10.1126/science.abd4585",
      "pmcid": "PMC7857397",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32972996/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32972996/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "IFN-autoAb-initial-overlaps-extension",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "natural experiment",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "Neutralizing IFN autoantibodies enriched in life-threatening disease blocked IFN antiviral activity in vitro.",
      "what_it_does_not_show": "Ascertainment and host age/sex matter; a causal susceptibility subgroup does not explain every severe case.",
      "confounders_present": [
        "Ascertainment and host age/sex matter; a causal susceptibility subgroup does not explain every severe case."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 44,
      "pmid": "32972995",
      "title": "Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.",
      "citation": "Zhang Q, Bastard P, Liu Z et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science (New York, N.Y.). 2020.",
      "doi": "10.1126/science.abd4570",
      "pmcid": "PMC7857407",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32972995/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32972995/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32972995",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "natural experiment",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "Functionally validated IFN-pathway deficiencies enriched in critical disease and increased cellular viral vulnerability.",
      "what_it_does_not_show": "Genetics precedes infection but clinical ascertainment and selected loci constrain population attribution.",
      "confounders_present": [
        "Genetics precedes infection but clinical ascertainment and selected loci constrain population attribution."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 45,
      "pmid": "34413139",
      "title": "Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.",
      "citation": "Bastard P, Gervais A, Le Voyer T et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science immunology. 2021.",
      "doi": "10.1126/sciimmunol.abl4340",
      "pmcid": "PMC8521484",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34413139/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34413139/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "IFN-autoAb-extension-includes-initial",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph0, 1:RESULTS:paragraph1, 1:RESULTS:paragraph2, 1:RESULTS:paragraph3, 1:RESULTS:paragraph4, 1:RESULTS:paragraph5, 1:RESULTS:paragraph6. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "natural experiment",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "More sensitive neutralization assays extended IFN-autoantibody susceptibility; available preinfection samples were positive.",
      "what_it_does_not_show": "566 critical patients and427 controls overlap the initial report; assay threshold and age alter prevalence estimates.",
      "confounders_present": [
        "566 critical patients and427 controls overlap the initial report; assay threshold and age alter prevalence estimates."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 46,
      "pmid": "35576468",
      "title": "The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.",
      "citation": "Manry J, Bastard P, Gervais A et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America. 2022.",
      "doi": "10.1073/pnas.2200413119",
      "pmcid": "PMC9173764",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35576468/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35576468/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "UpdateOf: PMID35043109"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "IFN-fatality-shared34159-controls",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "negative",
      "what_it_shows": "Age-stratified analyses estimated large autoantibody-associated fatality risk in unvaccinated individuals.",
      "what_it_does_not_show": "Shared34159 general-population comparator cohort; model-based IFR estimates are not an independent intervention.",
      "confounders_present": [
        "Shared34159 general-population comparator cohort; model-based IFR estimates are not an independent intervention."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 47,
      "pmid": "35708626",
      "title": "Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.",
      "citation": "Zhang Q, Matuozzo D, Le Pen J et al. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. The Journal of experimental medicine. 2022.",
      "doi": "10.1084/jem.20220131",
      "pmcid": "PMC9206114",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35708626/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35708626/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35708626",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "natural experiment",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "Children with complete IFN-signalling defects had severe pneumonia and vulnerable fibroblasts.",
      "what_it_does_not_show": "Rare pediatric genetic scope; not representative adult mortality or all inflammatory syndromes.",
      "confounders_present": [
        "Rare pediatric genetic scope; not representative adult mortality or all inflammatory syndromes."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 48,
      "pmid": "36880831",
      "title": "Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia.",
      "citation": "García-García A, Pérez de Diego R, Flores C et al. Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia. The Journal of experimental medicine. 2023.",
      "doi": "10.1084/jem.20220170",
      "pmcid": "PMC9998661",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36880831/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36880831/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID36880831",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "natural experiment",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "Inherited MyD88/IRAK4 deficiency predisposed to hypoxemic COVID with impaired TLR7 IFN production.",
      "what_it_does_not_show": "Small rare-disease cohort and broad signalling functions; demonstrates susceptibility rather than universal primacy.",
      "confounders_present": [
        "Small rare-disease cohort and broad signalling functions; demonstrates susceptibility rather than universal primacy."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 49,
      "pmid": "37020259",
      "title": "Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.",
      "citation": "Matuozzo D, Talouarn E, Marchal A et al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome medicine. 2023.",
      "doi": "10.1186/s13073-023-01173-8",
      "pmcid": "PMC10074346",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37020259/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37020259/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "UpdateOf: PMID36324795",
        "ErratumIn: PMID38184654"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID37020259",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "natural experiment",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "negative",
      "what_it_shows": "Rare-variant burden analysis supported prespecified IFN pathways and recessive TLR7 risk.",
      "what_it_does_not_show": "No gene reached genome-wide significance; pathway enrichment and linked erratum do not justify unrestricted genome-wide discovery claims.",
      "confounders_present": [
        "No gene reached genome-wide significance; pathway enrichment and linked erratum do not justify unrestricted genome-wide discovery claims."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 50,
      "pmid": "40185298",
      "title": "Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients.",
      "citation": "Antolí A, Gómez-Vázquez JL, Sierra-Fortuny A et al. Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients. Clinical immunology (Orlando, Fla.). 2025.",
      "doi": "10.1016/j.clim.2025.110491",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40185298/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40185298/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID40185298",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "negative",
      "what_it_shows": "IFN-neutralizing autoantibodies predicted critical pneumonia among vaccinated hospital patients in2021-2022.",
      "what_it_does_not_show": "Observational single hospital; later publication does not imply contemporary variant/treatment generality.",
      "confounders_present": [
        "Observational single hospital; later publication does not imply contemporary variant/treatment generality."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 51,
      "pmid": "33507309",
      "title": "High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019.",
      "citation": "Ouwendijk WJD, Raadsen MP, van Kampen JJA et al. High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019. The Journal of infectious diseases. 2021.",
      "doi": "10.1093/infdis/jiab050",
      "pmcid": "PMC7928833",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33507309/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33507309/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33507309",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4",
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "NETs persisted in lower airways and tracked viral load and severity; baseline plasma NETs did not track thrombosis.",
      "what_it_does_not_show": "Correlation and autopsy retention do not establish NET primacy or clinically effective NET inhibition.",
      "confounders_present": [
        "Correlation and autopsy retention do not establish NET primacy or clinically effective NET inhibition."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 52,
      "pmid": "32726800",
      "title": "Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.",
      "citation": "Carvelli J, Demaria O, Vély F et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020.",
      "doi": "10.1038/s41586-020-2600-6",
      "pmcid": "PMC7116884",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32726800/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32726800/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32726800",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4",
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational and model",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "positive",
      "what_it_shows": "C5a/C5aR1 tracked severity; specific blockade inhibited myeloid activation and lung injury in knock-in mice.",
      "what_it_does_not_show": "The abstract does not establish an infected-mouse endpoint; no direct primary systemic-cytokine or human causal test.",
      "confounders_present": [
        "The abstract does not establish an infected-mouse endpoint; no direct primary systemic-cytokine or human causal test."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 53,
      "pmid": "33079210",
      "title": "Inflammasome formation in the lungs of patients with fatal COVID-19.",
      "citation": "Toldo S, Bussani R, Nuzzi V et al. Inflammasome formation in the lungs of patients with fatal COVID-19. Inflammation research : official journal of the European Histamine Research Society ... [et al.]. 2021.",
      "doi": "10.1007/s00011-020-01413-2",
      "pmcid": "PMC7572246",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33079210/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33079210/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33079210",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4",
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "positive",
      "what_it_shows": "Fatal lungs showed inflammasome aggregates in injury areas versus historical controls.",
      "what_it_does_not_show": "Four fatal cases and four noninfected controls; presence does not prove inflammasome necessity.",
      "confounders_present": [
        "Four fatal cases and four noninfected controls; presence does not prove inflammasome necessity."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 54,
      "pmid": "38571960",
      "title": "Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS.",
      "citation": "Jonassen TB, Jørgensen SE, Mitchell NH et al. Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS. Frontiers in immunology. 2024.",
      "doi": "10.3389/fimmu.2024.1353012",
      "pmcid": "PMC10987806",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38571960/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38571960/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "Hvidovre-CARDS-overlap-with2021-unresolved",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph5, 1:Methods:paragraph6, 1:Methods:paragraph7, 2:Results:paragraph0, 2:Results:paragraph2, 2:Results:paragraph9, 2:Results:paragraph10, 2:Results:paragraph13, 2:Results:paragraph14, 2:Results:paragraph15, 2:Results:paragraph16, 2:Results:paragraph17. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Paired ELF-corrected study found alveolar IL8 compartmentalization and lower IL6 in steroid-treated CARDS.",
      "what_it_does_not_show": "Steroid groups were not randomized and differed in gas exchange; BAL autoantibody binding did not establish neutralization; unknown BAL cutoff.",
      "confounders_present": [
        "Steroid groups were not randomized and differed in gas exchange; BAL autoantibody binding did not establish neutralization; unknown BAL cutoff."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 55,
      "pmid": "39198643",
      "title": "Fibrin drives thromboinflammation and neuropathology in COVID-19.",
      "citation": "Ryu JK, Yan Z, Montano M et al. Fibrin drives thromboinflammation and neuropathology in COVID-19. Nature. 2024.",
      "doi": "10.1038/s41586-024-07873-4",
      "pmcid": "PMC11424477",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39198643/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39198643/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID39198643",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4",
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "animal model",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "Fibrin inflammatory-domain manipulation and antibody protection narrowed thromboinflammatory and neural injury mechanisms.",
      "what_it_does_not_show": "Model and antibody scope; no human trial demonstrating systemic-cytokine primacy or dominant mortality fraction.",
      "confounders_present": [
        "Model and antibody scope; no human trial demonstrating systemic-cytokine primacy or dominant mortality fraction."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 56,
      "pmid": "33915569",
      "title": "COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets.",
      "citation": "Delorey TM, Ziegler CGK, Heimberg G et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature. 2021.",
      "doi": "10.1038/s41586-021-03570-8",
      "pmcid": "PMC8919505",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33915569/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33915569/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33915569",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4",
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Multiorgan autopsy atlases mapped inflammatory and failed-repair states in viral-RNA-positive and negative regions.",
      "what_it_does_not_show": "End-stage selection and RNA localization do not prove replication, initiating cell type or primacy.",
      "confounders_present": [
        "End-stage selection and RNA localization do not prove replication, initiating cell type or primacy."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 57,
      "pmid": "32437596",
      "title": "Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.",
      "citation": "Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. The New England journal of medicine. 2020.",
      "doi": "10.1056/NEJMoa2015432",
      "pmcid": "PMC7412750",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32437596/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32437596/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32437596",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4",
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Autopsy comparison showed prominent microvascular thrombosis and angiogenesis versus influenza.",
      "what_it_does_not_show": "Small fatal-only series; ultrastructural virus identification and mechanism direction require independent verification.",
      "confounders_present": [
        "Small fatal-only series; ultrastructural virus identification and mechanism direction require independent verification."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 58,
      "pmid": "33163981",
      "title": "Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients.",
      "citation": "Mueller AA, Tamura T, Crowley CP et al. Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients. Cell reports. Medicine. 2020.",
      "doi": "10.1016/j.xcrm.2020.100144",
      "pmcid": "PMC7598305",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33163981/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33163981/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33163981",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "positive",
      "what_it_shows": "Rising CRP during first48h predicted respiratory deterioration better than initial levels.",
      "what_it_does_not_show": "Retrospective risk marker, no targeted causal or absolute cytokine-magnitude test.",
      "confounders_present": [
        "Retrospective risk marker, no targeted causal or absolute cytokine-magnitude test."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 59,
      "pmid": "33915568",
      "title": "A molecular single-cell lung atlas of lethal COVID-19.",
      "citation": "Melms JC, Biermann J, Huang H et al. A molecular single-cell lung atlas of lethal COVID-19. Nature. 2021.",
      "doi": "10.1038/s41586-021-03569-1",
      "pmcid": "PMC8814825",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33915568/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33915568/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "ErratumIn: PMID34625743"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33915568",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4",
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Fatal single-cell lung atlas linked cytokine-producing cells, immune dysfunction and failed alveolar repair.",
      "what_it_does_not_show": "End-stage transcriptomic/interaction inference; linked erratum remains unaudited; not direct concentration or intervention evidence.",
      "confounders_present": [
        "End-stage transcriptomic/interaction inference; linked erratum remains unaudited; not direct concentration or intervention evidence."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 60,
      "pmid": "34723652",
      "title": "The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients.",
      "citation": "McAleavy M, Zhang Q, Ehmann PJ et al. The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients. Molecular and cellular biology. 2022.",
      "doi": "10.1128/MCB.00467-21",
      "pmcid": "PMC8773081",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34723652/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34723652/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34723652",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational and model",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Activin/FLRG predicted poor outcomes; hamster blockade did not worsen viral load/pathology.",
      "what_it_does_not_show": "No positive improved disease endpoint in the abstract; absence of worsening is not efficacy or driver proof.",
      "confounders_present": [
        "No positive improved disease endpoint in the abstract; absence of worsening is not efficacy or driver proof."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 61,
      "pmid": "33146564",
      "title": "High-dimensional single-cell analysis reveals the immune characteristics of COVID-19.",
      "citation": "Shi W, Liu X, Cao Q et al. High-dimensional single-cell analysis reveals the immune characteristics of COVID-19. American journal of physiology. Lung cellular and molecular physiology. 2021.",
      "doi": "10.1152/ajplung.00355.2020",
      "pmcid": "PMC7869955",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33146564/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33146564/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33146564",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "positive",
      "what_it_shows": "Peripheral single-cell profiling described monocyte expansion, T-cell depletion and reduced antigen presentation.",
      "what_it_does_not_show": "Peripheral descriptive states do not establish causal direction or systemic hypercytokinemia magnitude.",
      "confounders_present": [
        "Peripheral descriptive states do not establish causal direction or systemic hypercytokinemia magnitude."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 62,
      "pmid": "34101213",
      "title": "SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation.",
      "citation": "Thorne LG, Reuschl AK, Zuliani-Alvarez L et al. SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. The EMBO journal. 2021.",
      "doi": "10.15252/embj.2021107826",
      "pmcid": "PMC8209947",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34101213/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34101213/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34101213",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "cell culture",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "positive",
      "what_it_shows": "RIGI/MDA5 and downstream inhibition reduced infected epithelial-to-macrophage inflammatory signalling.",
      "what_it_does_not_show": "Cultured primary-cell circuit, no in vivo necessity or compartment-specific mortality test.",
      "confounders_present": [
        "Cultured primary-cell circuit, no in vivo necessity or compartment-specific mortality test."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 63,
      "pmid": "34185704",
      "title": "IL-13 is a driver of COVID-19 severity.",
      "citation": "Donlan AN, Sutherland TE, Marie C et al. IL-13 is a driver of COVID-19 severity. JCI insight. 2021.",
      "doi": "10.1172/jci.insight.150107",
      "pmcid": "PMC8410056",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34185704/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34185704/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "UpdateOf: PMID33688686"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34185704",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4",
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "animal model",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "IL13 neutralization reduced infected-mouse mortality without lowering virus; CD44 blockade narrowed HA mediation.",
      "what_it_does_not_show": "Human dupilumab observations confounded; IL13/HA is not an IL6/IL1 clinical test nor systemic-storm magnitude proof.",
      "confounders_present": [
        "Human dupilumab observations confounded; IL13/HA is not an IL6/IL1 clinical test nor systemic-storm magnitude proof."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 64,
      "pmid": "40016339",
      "title": "IL-1β drives SARS-CoV-2-induced disease independently of the inflammasome and pyroptosis signalling.",
      "citation": "M Bader S, Scherer L, Schaefer J et al. IL-1β drives SARS-CoV-2-induced disease independently of the inflammasome and pyroptosis signalling. Cell death and differentiation. 2025.",
      "doi": "10.1038/s41418-025-01459-x",
      "pmcid": "PMC12284219",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40016339/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40016339/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID40016339",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "animal model",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "positive",
      "what_it_shows": "IL1beta loss improved infected-mouse disease/survival while several inflammasome/pyroptosis deletions did not.",
      "what_it_does_not_show": "Germline developmental and mouse-adapted-virus scope; cytokine causality does not establish the presumed release pathway.",
      "confounders_present": [
        "Germline developmental and mouse-adapted-virus scope; cytokine causality does not establish the presumed release pathway."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 65,
      "pmid": "33827897",
      "title": "SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation.",
      "citation": "Yan B, Freiwald T, Chauss D et al. SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Science immunology. 2021.",
      "doi": "10.1126/sciimmunol.abg0833",
      "pmcid": "PMC8139422",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33827897/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33827897/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "UpdateOf: PMID32702726"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33827897",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3",
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "cell culture",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "positive",
      "what_it_shows": "SARSCoV2 induced epithelial complement and JAK1/2 inhibition normalized selected genes/C3a.",
      "what_it_does_not_show": "Expression and cell inhibition do not establish human necessity, efficacy or dominant systemic lesion.",
      "confounders_present": [
        "Expression and cell inhibition do not establish human necessity, efficacy or dominant systemic lesion."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 66,
      "pmid": "32407669",
      "title": "Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients.",
      "citation": "Zhou Z, Ren L, Zhang L et al. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell host & microbe. 2020.",
      "doi": "10.1016/j.chom.2020.04.017",
      "pmcid": "PMC7196896",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32407669/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32407669/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32407669",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC5"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "positive",
      "what_it_shows": "BAL transcriptomes in eight cases showed inflammatory and IFN-stimulated signatures.",
      "what_it_does_not_show": "RNA is not secreted cytokine concentration; small disease-stage sampling; no causal compartment test.",
      "confounders_present": [
        "RNA is not secreted cytokine concentration; small disease-stage sampling; no causal compartment test."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 67,
      "pmid": "32979342",
      "title": "Compartmental immunophenotyping in COVID-19 ARDS: A case series.",
      "citation": "Ronit A, Berg RMG, Bay JT et al. Compartmental immunophenotyping in COVID-19 ARDS: A case series. The Journal of allergy and clinical immunology. 2021.",
      "doi": "10.1016/j.jaci.2020.09.009",
      "pmcid": "PMC7581505",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32979342/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32979342/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "Hvidovre-CARDS-overlap-with2024-unresolved",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph13, 1:Results:paragraph22, 2:Discussion:paragraph4, 2:Discussion:paragraph7, 2:Discussion:paragraph8, 0:Methods:paragraph0, 0:Methods:paragraph1, 0:Methods:paragraph2, 0:Methods:paragraph3, 0:Methods:paragraph4, 0:Methods:paragraph5, 0:Methods:paragraph6. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC5",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Four early-intubated cases showed lung and blood hyperinflammation, particularly lung IL8.",
      "what_it_does_not_show": "Raw BAL values were diluted; blood and BAL not universally discordant; selection and small sample limit generalization.",
      "confounders_present": [
        "Raw BAL values were diluted; blood and BAL not universally discordant; selection and small sample limit generalization."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    },
    {
      "n": 68,
      "pmid": "33187979",
      "title": "Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm.",
      "citation": "Mudd PA, Crawford JC, Turner JS et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Science advances. 2020.",
      "doi": "10.1126/sciadv.abe3024",
      "pmcid": "PMC7725462",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33187979/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33187979/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "UpdateOf: PMID32511543"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33187979",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "negative",
      "what_it_shows": "Only7 of168 COVID patients had storm-like profiles; adjusted cytokines were lower than influenza and IFN signatures suppressed.",
      "what_it_does_not_show": "Relative storm definition and observational sampling; shared comparative research network does not ensure all cohorts independent.",
      "confounders_present": [
        "Relative storm definition and observational sampling; shared comparative research network does not ensure all cohorts independent."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      }
    }
  ],
  "verification_summary": {
    "load_bearing_claims_checked": 74,
    "verified": 74,
    "unverified": 0,
    "contradicted": 0,
    "note": "Verified attribution is distinct from mechanism truth or complete body access."
  },
  "factual_issues_found": [],
  "cap_rules_applied": [
    {
      "subclaim_id": "SC1",
      "cap": "Β",
      "cap_source": "universal",
      "triggered": true,
      "trigger_text_quoted": "Inflammation association without pathway-specific causality caps at Β.",
      "specific_trigger": "Circulating IL6 and related markers predict deterioration and survival, including temporal validation [3-7,58]. This is a strong prognostic observation, not causal primacy.",
      "resulting_ceiling": "Β"
    }
  ],
  "cap_precedence_resolutions": [
    {
      "collision": "Perturbation in a defined setting versus broader inference",
      "subclaim_scope_cap_binds_on": "Systemic hypercytokinemia at a magnitude comparable to sepsis, hyperinflammatory ARDS or CAR-T cytokine release syndrome is the primary driver of severe COVID-19 pathology and mortality.",
      "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope",
      "resolution": "A perturbation crosses a threshold within its tested system; scope governs the inference beyond it. Rubric05 explicitly recognizes replicated single-target biologic hard-endpoint tests and inborn-errors natural experiments. SC3 is not held at Γ merely because other legs are observational. The full clinical convergent set supports Ζ contribution. It cannot identify systemic storm magnitude, localization or primacy, so SC4/SC5 remain Γ through missing causal attribution rather than a cap on the weakest study.",
      "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case."
    }
  ],
  "boundary_check_BGD": [
    {
      "subclaim_id": "SC1",
      "field_valid_perturbation_quote": "\n- Cell-type-specific conditional knockout or depletion\n- Pathway-specific blockade (not broad immunosuppression) changing disease course\n- Human targeted therapy with mechanistic alignment showing disease-modifying effect",
      "qualifying_evidence_present": "no",
      "qualifying_evidence_citation": "",
      "gamma_hard_rules_triggered": [],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "no",
      "perturbation_result_note": "Circulating IL6 and related markers predict deterioration and survival, including temporal validation [3-7,58]. This is a strong prognostic observation, not causal primacy.",
      "ceiling_from_boundary_check": "Γ"
    },
    {
      "subclaim_id": "SC2",
      "field_valid_perturbation_quote": "\n- Cell-type-specific conditional knockout or depletion\n- Pathway-specific blockade (not broad immunosuppression) changing disease course\n- Human targeted therapy with mechanistic alignment showing disease-modifying effect",
      "qualifying_evidence_present": "no",
      "qualifying_evidence_citation": "",
      "gamma_hard_rules_triggered": [],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "no",
      "perturbation_result_note": "Direct comparative observations are heterogeneous. The same-method ICU comparison and influenza comparison constrain general storm magnitude [1,68]; the small MFI-panel null [2] is not equivalence. The registered magnitude claim is not established across its scope.",
      "ceiling_from_boundary_check": "Γ"
    },
    {
      "subclaim_id": "SC3",
      "field_valid_perturbation_quote": "\n- Cell-type-specific conditional knockout or depletion\n- Pathway-specific blockade (not broad immunosuppression) changing disease course\n- Human targeted therapy with mechanistic alignment showing disease-modifying effect",
      "qualifying_evidence_present": "yes",
      "qualifying_evidence_citation": "PMID33933206, PMID33631065, PMID33332779, PMID34480127, PMID40360262, PMID32678530, PMID33306283, PMID35908569, PMID40016339",
      "gamma_hard_rules_triggered": [],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "yes",
      "perturbation_result_note": "IL6R-targeted mortality/organ-support benefits in separate RECOVERY and REMAP-CAP populations, placebo-controlled composite benefit in EMPACTA, and mechanistically different IL1 perturbation in SAVE-MORE reduce a purely passive-inflammatory-marker interpretation [13-15,18]. IL6R blockade is one causal line under the framework's independence test (agents of the same modality against the same target do not count twice, and replication adds confidence rather than a line); Ζ rests on its convergence with the mechanistically distinct IL1 blockade result and the infected-model IL1beta genetic contrast. IL1 clinical contribution is more selection-sensitive and bounded at Ε. Nulls identify boundaries rather than erasing all causal contribution [16-26,29-30].",
      "ceiling_from_boundary_check": "Δ or higher"
    },
    {
      "subclaim_id": "SC4",
      "field_valid_perturbation_quote": "\n- Cell-type-specific conditional knockout or depletion\n- Pathway-specific blockade (not broad immunosuppression) changing disease course\n- Human targeted therapy with mechanistic alignment showing disease-modifying effect",
      "qualifying_evidence_present": "no",
      "qualifying_evidence_citation": "PMID33933206, PMID33631065, PMID34480127, PMID40360262, PMID32678530, PMID32445440, PMID33306283, PMID35908569, PMID34351721, PMID34185704, PMID40016339",
      "gamma_hard_rules_triggered": [
        "Targeted contribution does not establish a primary systemic concentration-driven lesion."
      ],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "no",
      "perturbation_result_note": "Positive pathway-specific trials establish contribution, but cannot identify circulating magnitude or the fraction of disease primarily caused by that state. Host IFN natural experiments, antiviral benefit, vascular injury and compartment data make systemic-storm primacy mechanistically unestablished [32,37-50,54-57,68].",
      "ceiling_from_boundary_check": "Γ"
    },
    {
      "subclaim_id": "SC5",
      "field_valid_perturbation_quote": "\n- Cell-type-specific conditional knockout or depletion\n- Pathway-specific blockade (not broad immunosuppression) changing disease course\n- Human targeted therapy with mechanistic alignment showing disease-modifying effect",
      "qualifying_evidence_present": "no",
      "qualifying_evidence_citation": "PMID34185704",
      "gamma_hard_rules_triggered": [
        "Paired compartment association and systemic therapy do not locate the dominant causal action."
      ],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "no",
      "perturbation_result_note": "Systemic drug delivery does not localize pathogenic action. Paired blood/lung measurements show mediator-specific compartment relations and treatment effects, not proof that the disease-driving cytokine action is primarily systemic [11,51-54,65-67].",
      "ceiling_from_boundary_check": "Γ"
    }
  ],
  "thresholds_tested": [
    {
      "subclaim_id": "SC1",
      "threshold": "Δ",
      "requirement_quoted": "Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.",
      "satisfied": "no",
      "supporting_evidence": [],
      "what_would_cross_it": "Prediction alone cannot become a causal claim; retain descriptive scope."
    },
    {
      "subclaim_id": "SC2",
      "threshold": "Δ",
      "requirement_quoted": "Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.",
      "satisfied": "no",
      "supporting_evidence": [],
      "what_would_cross_it": "Harmonized assay, lot, symptom timing, treatment and severity comparators must establish the preregistered magnitude distribution rather than a selected extreme subgroup."
    },
    {
      "subclaim_id": "SC3",
      "threshold": "Δ",
      "requirement_quoted": "Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.",
      "satisfied": "yes",
      "supporting_evidence": [
        "[13] RECOVERY tocilizumab reduced primary 28-day ITT mortality in hypoxic CRP-at-least-75 patients, 31% versus 35%, RR0.85.",
        "[14] REMAP-CAP IL6R blockade improved organ-support-free days and survival within 24h of ICU organ support.",
        "[15] EMPACTA reduced ventilation-or-death composite in nonventilated hospitalized patients.",
        "[18] SAVE-MORE improved primary WHO-CPS with anakinra in suPAR-at-least-6 patients; mortality was lower in a separate survival analysis.",
        "[30] Expanded REMAP-CAP cohort supported equivalent IL6R agents and a null anakinra effect in critical patients.",
        "[31] RECOVERY low-dose dexamethasone reduced mortality on oxygen or ventilation, without benefit in no-oxygen patients.",
        "[33] ACTT2 baricitinib plus remdesivir accelerated recovery versus remdesivir.",
        "[35] RECOVERY baricitinib reduced primary ITT mortality, RR0.87, on extensive steroid background.",
        "[64] IL1beta loss improved infected-mouse disease/survival while several inflammasome/pyroptosis deletions did not."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC3",
      "threshold": "Ε",
      "requirement_quoted": "Requires context-specific causality with explicit scope restriction.",
      "satisfied": "yes",
      "supporting_evidence": [
        "[13] RECOVERY tocilizumab reduced primary 28-day ITT mortality in hypoxic CRP-at-least-75 patients, 31% versus 35%, RR0.85.",
        "[14] REMAP-CAP IL6R blockade improved organ-support-free days and survival within 24h of ICU organ support.",
        "[15] EMPACTA reduced ventilation-or-death composite in nonventilated hospitalized patients.",
        "[18] SAVE-MORE improved primary WHO-CPS with anakinra in suPAR-at-least-6 patients; mortality was lower in a separate survival analysis.",
        "[30] Expanded REMAP-CAP cohort supported equivalent IL6R agents and a null anakinra effect in critical patients.",
        "[31] RECOVERY low-dose dexamethasone reduced mortality on oxygen or ventilation, without benefit in no-oxygen patients.",
        "[33] ACTT2 baricitinib plus remdesivir accelerated recovery versus remdesivir.",
        "[35] RECOVERY baricitinib reduced primary ITT mortality, RR0.87, on extensive steroid background.",
        "[64] IL1beta loss improved infected-mouse disease/survival while several inflammasome/pyroptosis deletions did not."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC3",
      "threshold": "Ζ",
      "requirement_quoted": "Requires multiple convergent causal manipulations and reduced plausibility of downstream-only interpretations.",
      "satisfied": "yes",
      "supporting_evidence": [
        "[13] RECOVERY tocilizumab reduced primary 28-day ITT mortality in hypoxic CRP-at-least-75 patients, 31% versus 35%, RR0.85.",
        "[14] REMAP-CAP IL6R blockade improved organ-support-free days and survival within 24h of ICU organ support.",
        "[15] EMPACTA reduced ventilation-or-death composite in nonventilated hospitalized patients.",
        "[18] SAVE-MORE improved primary WHO-CPS with anakinra in suPAR-at-least-6 patients; mortality was lower in a separate survival analysis.",
        "[30] Expanded REMAP-CAP cohort supported equivalent IL6R agents and a null anakinra effect in critical patients.",
        "[31] RECOVERY low-dose dexamethasone reduced mortality on oxygen or ventilation, without benefit in no-oxygen patients.",
        "[33] ACTT2 baricitinib plus remdesivir accelerated recovery versus remdesivir.",
        "[35] RECOVERY baricitinib reduced primary ITT mortality, RR0.87, on extensive steroid background.",
        "[64] IL1beta loss improved infected-mouse disease/survival while several inflammasome/pyroptosis deletions did not."
      ],
      "what_would_cross_it": ""
    },
    {
      "subclaim_id": "SC3",
      "threshold": "Η",
      "requirement_quoted": "Requires robust upstream causal evidence across systems and interventions.",
      "satisfied": "no",
      "supporting_evidence": [
        "[13] RECOVERY tocilizumab reduced primary 28-day ITT mortality in hypoxic CRP-at-least-75 patients, 31% versus 35%, RR0.85.",
        "[14] REMAP-CAP IL6R blockade improved organ-support-free days and survival within 24h of ICU organ support.",
        "[15] EMPACTA reduced ventilation-or-death composite in nonventilated hospitalized patients.",
        "[18] SAVE-MORE improved primary WHO-CPS with anakinra in suPAR-at-least-6 patients; mortality was lower in a separate survival analysis.",
        "[30] Expanded REMAP-CAP cohort supported equivalent IL6R agents and a null anakinra effect in critical patients.",
        "[31] RECOVERY low-dose dexamethasone reduced mortality on oxygen or ventilation, without benefit in no-oxygen patients.",
        "[33] ACTT2 baricitinib plus remdesivir accelerated recovery versus remdesivir.",
        "[35] RECOVERY baricitinib reduced primary ITT mortality, RR0.87, on extensive steroid background.",
        "[64] IL1beta loss improved infected-mouse disease/survival while several inflammasome/pyroptosis deletions did not."
      ],
      "what_would_cross_it": "To reach Η, robust mechanistically aligned contributions must generalize prospectively across prespecified antiviral states, treatment eras and compartments without relying on inferred primacy."
    },
    {
      "subclaim_id": "SC4",
      "threshold": "Δ",
      "requirement_quoted": "Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.",
      "satisfied": "no",
      "supporting_evidence": [
        "[13] RECOVERY tocilizumab reduced primary 28-day ITT mortality in hypoxic CRP-at-least-75 patients, 31% versus 35%, RR0.85.",
        "[14] REMAP-CAP IL6R blockade improved organ-support-free days and survival within 24h of ICU organ support.",
        "[18] SAVE-MORE improved primary WHO-CPS with anakinra in suPAR-at-least-6 patients; mortality was lower in a separate survival analysis.",
        "[30] Expanded REMAP-CAP cohort supported equivalent IL6R agents and a null anakinra effect in critical patients.",
        "[31] RECOVERY low-dose dexamethasone reduced mortality on oxygen or ventilation, without benefit in no-oxygen patients.",
        "[32] ACTT1 remdesivir improved primary recovery time versus placebo.",
        "[33] ACTT2 baricitinib plus remdesivir accelerated recovery versus remdesivir.",
        "[35] RECOVERY baricitinib reduced primary ITT mortality, RR0.87, on extensive steroid background.",
        "[38] Therapeutic heparin improved survival-to-discharge without organ support in noncritical hospitalized patients.",
        "[63] IL13 neutralization reduced infected-mouse mortality without lowering virus; CD44 blockade narrowed HA mediation.",
        "[64] IL1beta loss improved infected-mouse disease/survival while several inflammasome/pyroptosis deletions did not."
      ],
      "what_would_cross_it": "Estimate cytokine-attributable disease burden with early specific pathway/compartment interventions versus viral and vascular alternatives; benefit must identify the dominant lesion rather than merely an amplifier."
    },
    {
      "subclaim_id": "SC5",
      "threshold": "Δ",
      "requirement_quoted": "Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.",
      "satisfied": "no",
      "supporting_evidence": [
        "[63] IL13 neutralization reduced infected-mouse mortality without lowering virus; CD44 blockade narrowed HA mediation."
      ],
      "what_would_cross_it": "Compare validated compartment-restricted perturbations with matched target engagement, systemic exposure and hard outcomes; circulating biomarkers alone do not establish localization."
    }
  ],
  "generalization_check": {
    "generalization_tested": "yes",
    "context_boundary_mapped": "yes",
    "internal_negative_controls": [
      "COVACTA and BACC IL6 primary nulls [16-17]",
      "REMDACTA null despite high steroid use [29]",
      "Critical-care anakinra null versus early suPAR-enriched SAVE-MORE [18,30]",
      "Higher-dose steroid harm in no/simple-oxygen patients [36]",
      "Inflammasome/pyroptosis deletion nulls versus IL1beta knockout benefit [64]"
    ],
    "note": "Baseline respiratory support, CRP/suPAR eligibility, dose and symptom timing were defined before outcomes. They map real boundaries; post hoc steroid/ferritin responders are not used to redefine the claim. Most efficacy enrollment predates broad vaccination and Omicron. Later IFN-autoantibody vaccinated evidence extends a susceptibility association, not contemporary IL6 efficacy or general storm primacy."
  },
  "falsification_patterns_met": [
    {
      "pattern": "Specific block is context-dependent",
      "evidence": "Several IL6/IL1 trials have null primary outcomes despite inflammatory enrollment [16-26,29-30].",
      "downgrade_applied": false
    },
    {
      "pattern": "Mechanism inferred from a marker is not necessary",
      "evidence": "IFN susceptibility and compartment injury are compatible with severe disease without universal comparator-magnitude blood cytokines [1,43-50,54,68].",
      "downgrade_applied": false
    },
    {
      "pattern": "Release pathway is dispensable despite mediator contribution",
      "evidence": "IL1beta loss helped infected mice while multiple canonical processing/pyroptosis deletions did not [64].",
      "downgrade_applied": false
    }
  ],
  "pitfalls_flagged": [
    {
      "pitfall": "Therapeutic benefit converted to primacy",
      "where": "RECOVERY/REMAP-CAP pathway effects do not locate cytokine action or quantify dominance [13-14]."
    },
    {
      "pitfall": "Prognostic marker treated as predictive treatment selector",
      "where": "IL6 prediction and exploratory ferritin interactions have different evidential roles [5-6,28]."
    },
    {
      "pitfall": "Null treated as equivalence",
      "where": "Wilson MFI panel and ACTT4 active comparator are not equivalence proofs [2,40]."
    },
    {
      "pitfall": "Secondary outcome promoted to primary success",
      "where": "EMPACTA, COV-BARRIER and tixagevimab trials have different endpoint hierarchies [15,34,41]."
    },
    {
      "pitfall": "Binding antibody confused with neutralization",
      "where": "BAL IFN autoantibody ELISA differs from functional neutralization assays [45,54]."
    },
    {
      "pitfall": "Publication year mistaken for enrollment era",
      "where": "The expanded REMAP-CAP report was published in2025 but enrolled in2020-2021 [30]."
    }
  ],
  "causal_tally_audit": {
    "tally_claimed_by_document": 12,
    "tally_after_audit": 12,
    "items_rejected": [
      "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.",
      "Positive causal flags are scoped disease-modifying contrasts, not independent lines or primacy successes. Broad steroid/JAK and antiviral/heparin benefits are distinguished from single-target cytokine evidence. IFN natural experiments support the rival, not the nominal cytokine claim."
    ]
  },
  "steelman": {
    "case_one_rung_higher": "The strongest case for Δ primacy is that specific IL6R blockade repeatedly changes survival or organ support, early suPAR-guided IL1 blockade works, and mouse cytokine perturbations change disease despite unchanged virus [13-15,18,63-64]. Those findings decisively reject a wholly passive inflammatory role.",
    "case_one_rung_lower": "The strongest case for Β is that the blood-magnitude and primacy claims remain observational and direct comparator studies challenge a general storm [1-2,68]. It misses disease-modifying, target-specific clinical perturbations and mechanistic mediator experiments.",
    "which_rejected": "Reject Δ for the registered primacy gate because contribution, magnitude and localization have not been causally joined. Reject Β for the overall mechanistic hypothesis because active cytokine contributions are established. Retain Γ for nominal primacy and explicitly preserve Ζ for SC3 rather than downgrade the genuine clinical causal evidence.",
    "blocking_cap_threshold_or_missing_experiment": "Missing experiment: Prospectively enroll prespecified early severe-COVID strata across vaccination/variant and antiviral states; use harmonized contemporaneous blood and dilution-corrected pulmonary cytokine measurements. Randomize mechanistically aligned cytokine blockade with matched antiviral care and factorial vascular treatment where ethical; add a validated compartment-selective instrument in an infected model. Estimate prespecified mediators and attributable outcome effects without defining groups by treatment response."
  },
  "final_score": {
    "hsef_level": "Γ",
    "hsef_descriptor": "Mechanistically plausible, partial system support",
    "confidence": "Moderate",
    "confidence_rationale": "68 primary reports with 8 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
    "rests_on_non_peer_reviewed_work": false,
    "rationale": "The preregistered scope-matched gate SC4 yields Γ / Moderate for systemic-storm primacy. SC3 earns Ζ for convergent targeted cytokine contribution in prespecified hospitalized contexts; this is explicitly retained. Weakest-link sensitivity is Β because SC1/SC2 are descriptive observations. Primary-subclaim and scope-matched sensitivities are Γ. Treatable inflammation and a cytokine-first systemic magnitude claim are different propositions."
  },
  "role_of_mechanism": {
    "classification": "reinforcing / stabilizing factor",
    "derivation_step_matched": 5,
    "derivation": "Specific cytokine signalling can amplify disease after infection and antiviral failure. Human targeted interventions establish contribution and some survival effects, but do not establish initiation, necessary storm magnitude, or primary systemic action. No rate-limiting or universal mechanism role is inferred from a treatment response.",
    "tournament_used_as_tiebreaker": false,
    "note": "Derived from causal direction, not tournament rank."
  },
  "extended_scoring_MSD": {
    "momentum": {
      "value": "Mechanistic only",
      "artifact": "The 2025 infected-mouse IL1beta versus inflammasome/pyroptosis contrasts [64] and expanded REMAP-CAP IL6/IL1 comparison [30] discriminate mediators and timing; the latter is an older-enrollment cohort extension.",
      "justification": "The 2025 infected-mouse IL1beta versus inflammasome/pyroptosis contrasts [64] and expanded REMAP-CAP IL6/IL1 comparison [30] discriminate mediators and timing; the latter is an older-enrollment cohort extension."
    },
    "stability": {
      "value": "Stable",
      "trigger": "No verified imminent trial is used to forecast a level change. Assay-harmonized early paired sampling and compartment-specific intervention could change the primacy inference, but no such pending result is claimed.",
      "justification": "No verified imminent trial is used to forecast a level change. Assay-harmonized early paired sampling and compartment-specific intervention could change the primacy inference, but no such pending result is claimed."
    },
    "divergence": {
      "implied_level": null,
      "implied_level_basis": "No single field-implied level is defensible from conflicting framings.",
      "assessed_level": "Γ",
      "gap_in_rungs": null,
      "value": "Contested",
      "justification": "No manufactured field consensus or arithmetic gap."
    },
    "calibration_note": "M/S/D never modify HSEF level or confidence."
  },
  "change_record": {
    "applies": false,
    "prior_level": "Ranking categorical verdict visible; no prior letter used as a target",
    "prior_confidence": null,
    "prior_source": null,
    "derived_before_consulting_prior": false,
    "new_level": "Γ",
    "direction": "newly assigned",
    "what_moved_it": "Fresh primary evidence appraisal; not blinded.",
    "divergence_from_other_reviewers": null
  },
  "proposed_decisive_experiments": [
    {
      "name": "Registered boundary experiment",
      "experiment": "Prospectively enroll prespecified early severe-COVID strata across vaccination/variant and antiviral states; use harmonized contemporaneous blood and dilution-corrected pulmonary cytokine measurements. Randomize mechanistically aligned cytokine blockade with matched antiviral care and factorial vascular treatment where ethical; add a validated compartment-selective instrument in an infected model. Estimate prespecified mediators and attributable outcome effects without defining groups by treatment response.",
      "readout": "Mortality and organ-support-free days, viral burden, cytokine target engagement in both compartments, vascular injury and repair, with prespecified longitudinal mediator models",
      "critical_control": "Matched assays/lots and sampling, blinded outcome assessment, baseline steroid/antiviral stratification, drug exposure, non-COVID infectious ARDS comparators and registered multiplicity",
      "supporting_result": "Comparator-magnitude circulating elevation temporally precedes injury and explains the dominant specifically reversible disease component across prespecified strata after viral/vascular alternatives are addressed",
      "falsifying_result": "Severe injury and mortality persist without the specified systemic magnitude, local target engagement predicts benefit better than blood magnitude, or independently controlled viral/vascular processes explain the predominant outcome effect"
    }
  ],
  "knowledge_gaps": [
    {
      "name": "Gap 1",
      "statement": "Early longitudinal paired lung/blood cytokine measurements with harmonized assays, BAL dilution correction and matched non-COVID comparator severity.",
      "relevance": "Limits mechanism identification or scope."
    },
    {
      "name": "Gap 2",
      "statement": "Prospective predictive treatment selectors that separate prognosis from pathway-specific response without post hoc responder definitions.",
      "relevance": "Limits mechanism identification or scope."
    },
    {
      "name": "Gap 3",
      "statement": "Compartment-restricted causal interventions with validated target engagement and hard outcomes; systemic delivery cannot identify location.",
      "relevance": "Limits mechanism identification or scope."
    },
    {
      "name": "Gap 4",
      "statement": "Factorial antiviral, cytokine and vascular tests with prespecified mediation and outcome attribution, preserving endpoint hierarchy.",
      "relevance": "Limits mechanism identification or scope."
    },
    {
      "name": "Gap 5",
      "statement": "Reassess efficacy boundaries in vaccinated contemporary-variant patients rather than equating recent publication with current enrollment.",
      "relevance": "Limits mechanism identification or scope."
    },
    {
      "name": "Gap 6",
      "statement": "Audit linked corrections, protocols and complete supplements before publication; quantify report-family and biobank overlap.",
      "relevance": "Limits mechanism identification or scope."
    }
  ],
  "review_metadata": {
    "review_date": "2026-10-05",
    "reviewer": "Codex",
    "evidence_base_note": "68 primary reports; cutoff 2026-10-05; bounded critical review, not exhaustive systematic review.",
    "literature_tools_available": true,
    "literature_tools_note": "Life Sciences Literature PubMed/Europe PMC; signed-in Consensus browser discovery and indexed full-text extraction; independent checks against original sections. Zero Consensus API calls.",
    "skill_version": "5.3",
    "validator_run": "exact archived v5.3 validator 2.3; see validator.txt",
    "validator_warnings_addressed": "Phenomenon entry was restated as the preregistered causal claim. No real phenomenon is labelled refuted; warning is explicitly justified.",
    "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible."
  },
  "is_calibration_entry": {
    "value": false,
    "entry_role": "not_calibration",
    "blind_graded": null,
    "completed_blinded_calibration": false,
    "expected_band_sealed_at": "",
    "target_sha256": "",
    "target_authorship": "not applicable",
    "target_author_saw_review": null,
    "future_run_status": "not prepared",
    "unblinded_reason": "Ranking categorical verdict and index guidance were visible. No completed blinded calibration claimed."
  },
  "upper_ladder_check": {
    "final_level_below_zeta": true,
    "equivalents_considered": [
      {
        "kind": "mendelian_randomization",
        "available": false,
        "why_not_sufficient": "Target-specific IL6R hard-outcome studies form one causal line; together with the mechanistically distinct IL1 blockade result and the infected-model IL1beta contrast they carry SC3 to Ζ; functional human IFN genetic/autoimmune natural experiments support a scoped Ζ rival. Higher levels are live. These instruments do not establish comparator-magnitude systemic hypercytokinemia as the dominant lesion, so SC4 remains Γ without re-capping convergence. Broad immunosuppression contributes less specificity; a generic RCT requirement is not imposed."
      },
      {
        "kind": "natural_experiment",
        "available": true,
        "why_not_sufficient": "Target-specific IL6R hard-outcome studies form one causal line; together with the mechanistically distinct IL1 blockade result and the infected-model IL1beta contrast they carry SC3 to Ζ; functional human IFN genetic/autoimmune natural experiments support a scoped Ζ rival. Higher levels are live. These instruments do not establish comparator-magnitude systemic hypercytokinemia as the dominant lesion, so SC4 remains Γ without re-capping convergence. Broad immunosuppression contributes less specificity; a generic RCT requirement is not imposed."
      },
      {
        "kind": "dose_response_across_populations",
        "available": false,
        "why_not_sufficient": "Target-specific IL6R hard-outcome studies form one causal line; together with the mechanistically distinct IL1 blockade result and the infected-model IL1beta contrast they carry SC3 to Ζ; functional human IFN genetic/autoimmune natural experiments support a scoped Ζ rival. Higher levels are live. These instruments do not establish comparator-magnitude systemic hypercytokinemia as the dominant lesion, so SC4 remains Γ without re-capping convergence. Broad immunosuppression contributes less specificity; a generic RCT requirement is not imposed."
      },
      {
        "kind": "withdrawal_rechallenge",
        "available": false,
        "why_not_sufficient": "Target-specific IL6R hard-outcome studies form one causal line; together with the mechanistically distinct IL1 blockade result and the infected-model IL1beta contrast they carry SC3 to Ζ; functional human IFN genetic/autoimmune natural experiments support a scoped Ζ rival. Higher levels are live. These instruments do not establish comparator-magnitude systemic hypercytokinemia as the dominant lesion, so SC4 remains Γ without re-capping convergence. Broad immunosuppression contributes less specificity; a generic RCT requirement is not imposed."
      },
      {
        "kind": "therapeutic_perturbation_hard_endpoint",
        "available": true,
        "why_not_sufficient": "Target-specific IL6R hard-outcome studies form one causal line; together with the mechanistically distinct IL1 blockade result and the infected-model IL1beta contrast they carry SC3 to Ζ; functional human IFN genetic/autoimmune natural experiments support a scoped Ζ rival. Higher levels are live. These instruments do not establish comparator-magnitude systemic hypercytokinemia as the dominant lesion, so SC4 remains Γ without re-capping convergence. Broad immunosuppression contributes less specificity; a generic RCT requirement is not imposed."
      }
    ],
    "convergence_present": true,
    "cap_reapplied_to_convergent_set": false
  },
  "provenance_header": {
    "sources_total": 68,
    "claims_total": 74,
    "claims_verified": 74,
    "claims_unverified": 0,
    "claims_contradicted": 0,
    "tier_a_sources": 68,
    "generated_by": "Codex; HSEF v5.3",
    "gate_passed": true
  },
  "claims": [
    {
      "id": "C1",
      "text": "Same-method ICU comparison found lower circulating IL6 in COVID ARDS than septic-shock ARDS. Historical cohorts, timing, disease severity and unmeasured assay-lot variability constrain magnitude inference.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC4"
      ],
      "source_ns": [
        1
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: Publisher Methods, Results and Discussion, displayed lines 141-196; summary receipt. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C2",
      "text": "Small same-panel comparison detected no significant cytokine differences between COVID, ARDS and sepsis. Luminex MFI cannot be converted to comparable pg/mL; low power and nonsignificance do not establish equivalence.",
      "carries_number": false,
      "load_bearing_for": [
        "SC2",
        "SC4"
      ],
      "source_ns": [
        2
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph1, 1:Results:paragraph2, 1:Results:paragraph3, 2:Discussion:paragraph0, 2:Discussion:paragraph1, 2:Discussion:paragraph3, 2:Discussion:paragraph4, 3:Methods:paragraph1, 3:Methods:paragraph2, 3:Methods:paragraph3, 3:Methods:paragraph4, 3:Methods:paragraph5. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C3",
      "text": "Moderate cytokine increases in 24 ICU patients correlated with respiratory and kidney failure; IL8 had the strongest mortality signal. Surgical controls do not test magnitude against matched sepsis; correlation does not establish primacy.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        3
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C4",
      "text": "Admission profiles predicted mortality differently by respiratory-support category, with a validation cohort. Prognostic profiles and antigen associations do not identify a universal cytokine-first cause.",
      "carries_number": false,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        4
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C5",
      "text": "Admission IL6 and TNF predicted severity and death after adjustment in 1484 patients and a second cohort. Adjusted prediction is not randomized causal attribution; index inflammatory framing is not accepted as a result.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        5
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C6",
      "text": "Peak IL6 and CRP before intubation predicted respiratory failure in development and temporal validation cohorts. Peak measurements are time-varying risk markers; cutoffs are not storm definitions or proof of causality.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        6
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C7",
      "text": "Serial immune profiles in 113 patients linked early cytokines and sustained maladapted responses to severe trajectories. Associations can reflect viral burden and tissue injury; no pathway-specific intervention.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        7
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C8",
      "text": "COVID leukocytes had impaired stimulated IFNgamma/TNF production relative to critical controls; ex vivo IL7 restored T-cell output. Ex vivo functional suppression can coexist with local inflammation; no in vivo IL7 outcome test.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC4"
      ],
      "source_ns": [
        8
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C9",
      "text": "COVID and bacterial sepsis differed in early inflammation and longitudinal immune suppression over 21 days. Small cohorts, treatment and timing confounding; no dominant causal pathway attribution.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC4"
      ],
      "source_ns": [
        9
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C10",
      "text": "Innate hyperresponsiveness and adaptive dysfunction coexisted in 147 patients; clustering found no specific endotypes. Functional blood assays do not establish systemic primacy or exclude tissue-specific endotypes.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        10
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C11",
      "text": "Matched blood/BAL study found lower-airway cytokine elevations in severe viral disease; only IP10 correlated between compartments. Sampling and lavage dilution limit absolute comparisons; compartment association is not compartment-specific causality.",
      "carries_number": true,
      "load_bearing_for": [
        "SC5",
        "SC4"
      ],
      "source_ns": [
        11
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C12",
      "text": "Longitudinal critical-pneumonia comparison distinguished COVID exhaustion and immune-recognition signatures from shared myelopoiesis. Predicted HLA binding and profiling are associative; linked erratum details remain unaudited.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        12
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C13",
      "text": "RECOVERY tocilizumab reduced primary 28-day ITT mortality in hypoxic CRP-at-least-75 patients, 31% versus 35%, RR0.85. Open label; 82% on steroids; effect identifies IL6R contribution, not circulating concentration, compartment or primary cause.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        13
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph6, 1:Methods:paragraph7, 1:Methods:paragraph8, 1:Methods:paragraph9, 1:Methods:paragraph11, 1:Methods:paragraph12, 2:Results:paragraph0, 2:Results:paragraph2, 2:Results:paragraph9, 2:Results:paragraph10, 2:Results:paragraph11, 2:Results:paragraph13, 2:Results:paragraph14, 2:Results:paragraph15, 2:Results:paragraph16. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C14",
      "text": "REMAP-CAP IL6R blockade improved organ-support-free days and survival within 24h of ICU organ support. Adaptive open-label platform and concomitant treatments; initial sarilumab arm small; does not identify systemic magnitude or primacy.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        14
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C15",
      "text": "EMPACTA reduced ventilation-or-death composite in nonventilated hospitalized patients. Mortality alone did not improve; composite benefit must not be called survival benefit.",
      "carries_number": false,
      "load_bearing_for": [
        "SC3"
      ],
      "source_ns": [
        15
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C16",
      "text": "COVACTA placebo-controlled tocilizumab trial was null for primary day28 clinical status and mortality. Different eligibility and treatment background from RECOVERY; confidence intervals do not exclude all context-specific effects.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        16
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C17",
      "text": "BACC trial found no significant prevention of intubation or death with tocilizumab in moderately ill nonventilated patients. Wide intervals, small trial and early treatment era; not proof IL6 never contributes.",
      "carries_number": false,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        17
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C18",
      "text": "SAVE-MORE improved primary WHO-CPS with anakinra in suPAR-at-least-6 patients; mortality was lower in a separate survival analysis. Excluded P/F below150 and NIV/MV; 85.9% on dexamethasone; WHO endpoint hierarchy differs from mortality-primary trials; linked correction not fully audited.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        18
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph6, 1:Results:paragraph7, 1:Results:paragraph8, 1:Results:paragraph12, 1:Results:paragraph14, 1:Results:paragraph15, 2:Discussion:paragraph5, 2:Discussion:paragraph6, 3:Methods:paragraph0, 3:Methods:paragraph2, 3:Methods:paragraph3, 3:Methods:paragraph4, 3:Methods:paragraph6, 3:Methods:paragraph7. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C19",
      "text": "CORIMUNO-ANA-1 found no benefit on coprimary ventilation/death outcomes with anakinra. Early stopped small open-label trial with different CRP eligibility and treatment era from SAVE-MORE.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        19
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C20",
      "text": "CAN-COVID canakinumab did not significantly improve survival without invasive ventilation. Targets IL1beta rather than both IL1alpha/beta; a null does not establish pathway equivalence or universal absence.",
      "carries_number": false,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        20
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C21",
      "text": "Blinded multinational sarilumab trial did not improve primary clinical improvement or day29 survival. Numerical critical-subgroup survival difference was not significant; exploratory subsets cannot define the claim.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3"
      ],
      "source_ns": [
        21
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C22",
      "text": "Adaptive sarilumab phase2/3 trial missed its primary endpoint; pooled post hoc steroid subgroup suggested benefit. Post hoc subgroup and low steroid background in primary ventilated population limit causal subgroup claims.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3"
      ],
      "source_ns": [
        22
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C23",
      "text": "SARICOR400 showed a nonsignificant trend toward less respiratory progression in inflammatory pneumonia. Phase2 open-label sample115; trend and zero deaths in one arm are not confirmatory efficacy.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3"
      ],
      "source_ns": [
        23
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C24",
      "text": "ANA-COVID-GEAS did not prevent mechanical ventilation or reduce mortality with anakinra. Open label; selected severe hyperinflammatory population differs from suPAR selection; no universal pathway falsification.",
      "carries_number": false,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        24
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C25",
      "text": "COV-AID factorial IL1/IL6 strategies did not shorten primary clinical-improvement time or show a mortality difference. Low baseline mortality, serum entry criteria and factorial dosing contexts constrain scope.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        25
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C26",
      "text": "Small anakinra trial stopped early and showed worse day14 treatment success than optimized care. Only71 of planned240; safety signal and uncertainty must be retained rather than generalized to all anakinra settings.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        26
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C27",
      "text": "SAVE-MORE transcriptomic substudy associated anakinra with endotype transitions and respiratory-failure protection. Same trial family as primary SAVE-MORE; post-treatment endotype differences are not independently randomized mediators.",
      "carries_number": false,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        27
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C28",
      "text": "COVACTA exploratory biomarkers were prognostic; ferritin interactions suggested treatment-effect prediction. Same COVACTA family; exploratory interactions and linked erratum not independent efficacy replication.",
      "carries_number": false,
      "load_bearing_for": [
        "SC1",
        "SC3"
      ],
      "source_ns": [
        28
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C29",
      "text": "REMDACTA tocilizumab plus remdesivir did not improve primary discharge time, with 88.2% receiving steroids. Steroid use alone cannot explain every IL6 null; trial was not a mortality-primary precision test.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        29
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C30",
      "text": "Expanded REMAP-CAP cohort supported equivalent IL6R agents and a null anakinra effect in critical patients. 2025 publication enrolled March2020-April2021 and extends the original domain; not a fresh 2025 population replication.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        30
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C31",
      "text": "RECOVERY low-dose dexamethasone reduced mortality on oxygen or ventilation, without benefit in no-oxygen patients. Pleiotropic steroid effects do not isolate a cytokine; same platform can share co-randomized patients and controls.",
      "carries_number": false,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        31
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C32",
      "text": "ACTT1 remdesivir improved primary recovery time versus placebo. Mortality CI included no effect; antiviral efficacy does not quantify the fraction of death driven by virus versus inflammation.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        32
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C33",
      "text": "ACTT2 baricitinib plus remdesivir accelerated recovery versus remdesivir. Mortality interval included null; JAK1/2 affects several pathways and cannot identify one circulating cytokine.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        33
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C34",
      "text": "COV-BARRIER missed primary progression endpoint but showed nominal secondary mortality reduction. Failed hierarchy makes mortality p-values non-multiplicity-controlled; original Methods and Results explicitly confirm this.",
      "carries_number": false,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        34
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph7, 1:Methods:paragraph8, 1:Methods:paragraph9, 1:Methods:paragraph10, 1:Methods:paragraph11, 2:Results:paragraph11, 2:Results:paragraph12, 2:Results:paragraph13, 2:Results:paragraph18, 2:Results:paragraph19, 2:Results:paragraph20, 2:Results:paragraph21. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C35",
      "text": "RECOVERY baricitinib reduced primary ITT mortality, RR0.87, on extensive steroid background. JAK blockade is broader than IL6R blockade; concurrent tocilizumab and shared platform complicate line-counting.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        35
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C36",
      "text": "Higher-dose dexamethasone increased mortality versus usual low-dose care in no/simple-oxygen patients. Dose and baseline support are prespecified boundaries; harm does not negate low-dose benefit in other contexts.",
      "carries_number": false,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        36
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C37",
      "text": "Therapeutic heparin was futile for organ-support-free days in critical COVID. Therapeutic anticoagulation is not all immunothrombosis; late irreversible injury and bleeding constrain inference.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        37
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C38",
      "text": "Therapeutic heparin improved survival-to-discharge without organ support in noncritical hospitalized patients. Bleeding increased; anticoagulant and other heparin actions do not isolate systemic cytokine primacy.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        38
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C39",
      "text": "ACTT3 late IFNbeta plus remdesivir did not improve recovery and high-flow patients had worse outcomes. Treatment after symptoms does not falsify inherited early IFN protection; timing and molecule matter.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        39
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C40",
      "text": "ACTT4 found similar ventilation-free survival with baricitinib versus dexamethasone, both plus remdesivir. Active comparator, no untreated control; nonsignificance does not prove mechanistic equivalence.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        40
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C41",
      "text": "Hospitalized tixagevimab/cilgavimab trial missed primary sustained recovery; secondary mortality was lower. Primary null, background remdesivir and variant-specific antibody activity limit broad viral-primacy conclusions; correction retained.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        41
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C42",
      "text": "ACTT1 substudy linked blood viral markers, remdesivir clearance effects and clinical benefit. Same ACTT1 family; biomarker mediation was not itself randomized and respiratory/blood measures differed.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        42
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C43",
      "text": "Neutralizing IFN autoantibodies enriched in life-threatening disease blocked IFN antiviral activity in vitro. Ascertainment and host age/sex matter; a causal susceptibility subgroup does not explain every severe case.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        43
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C44",
      "text": "Functionally validated IFN-pathway deficiencies enriched in critical disease and increased cellular viral vulnerability. Genetics precedes infection but clinical ascertainment and selected loci constrain population attribution.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        44
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C45",
      "text": "More sensitive neutralization assays extended IFN-autoantibody susceptibility; available preinfection samples were positive. 566 critical patients and427 controls overlap the initial report; assay threshold and age alter prevalence estimates.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        45
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph0, 1:RESULTS:paragraph1, 1:RESULTS:paragraph2, 1:RESULTS:paragraph3, 1:RESULTS:paragraph4, 1:RESULTS:paragraph5, 1:RESULTS:paragraph6. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C46",
      "text": "Age-stratified analyses estimated large autoantibody-associated fatality risk in unvaccinated individuals. Shared34159 general-population comparator cohort; model-based IFR estimates are not an independent intervention.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        46
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C47",
      "text": "Children with complete IFN-signalling defects had severe pneumonia and vulnerable fibroblasts. Rare pediatric genetic scope; not representative adult mortality or all inflammatory syndromes.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        47
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C48",
      "text": "Inherited MyD88/IRAK4 deficiency predisposed to hypoxemic COVID with impaired TLR7 IFN production. Small rare-disease cohort and broad signalling functions; demonstrates susceptibility rather than universal primacy.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        48
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C49",
      "text": "Rare-variant burden analysis supported prespecified IFN pathways and recessive TLR7 risk. No gene reached genome-wide significance; pathway enrichment and linked erratum do not justify unrestricted genome-wide discovery claims.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        49
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C50",
      "text": "IFN-neutralizing autoantibodies predicted critical pneumonia among vaccinated hospital patients in2021-2022. Observational single hospital; later publication does not imply contemporary variant/treatment generality.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        50
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C51",
      "text": "NETs persisted in lower airways and tracked viral load and severity; baseline plasma NETs did not track thrombosis. Correlation and autopsy retention do not establish NET primacy or clinically effective NET inhibition.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4",
        "SC5"
      ],
      "source_ns": [
        51
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C52",
      "text": "C5a/C5aR1 tracked severity; specific blockade inhibited myeloid activation and lung injury in knock-in mice. The abstract does not establish an infected-mouse endpoint; no direct primary systemic-cytokine or human causal test.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4",
        "SC5"
      ],
      "source_ns": [
        52
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C53",
      "text": "Fatal lungs showed inflammasome aggregates in injury areas versus historical controls. Four fatal cases and four noninfected controls; presence does not prove inflammasome necessity.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4",
        "SC5"
      ],
      "source_ns": [
        53
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C54",
      "text": "Paired ELF-corrected study found alveolar IL8 compartmentalization and lower IL6 in steroid-treated CARDS. Steroid groups were not randomized and differed in gas exchange; BAL autoantibody binding did not establish neutralization; unknown BAL cutoff.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC5"
      ],
      "source_ns": [
        54
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph5, 1:Methods:paragraph6, 1:Methods:paragraph7, 2:Results:paragraph0, 2:Results:paragraph2, 2:Results:paragraph9, 2:Results:paragraph10, 2:Results:paragraph13, 2:Results:paragraph14, 2:Results:paragraph15, 2:Results:paragraph16, 2:Results:paragraph17. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C55",
      "text": "Fibrin inflammatory-domain manipulation and antibody protection narrowed thromboinflammatory and neural injury mechanisms. Model and antibody scope; no human trial demonstrating systemic-cytokine primacy or dominant mortality fraction.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4",
        "SC5"
      ],
      "source_ns": [
        55
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C56",
      "text": "Multiorgan autopsy atlases mapped inflammatory and failed-repair states in viral-RNA-positive and negative regions. End-stage selection and RNA localization do not prove replication, initiating cell type or primacy.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4",
        "SC5"
      ],
      "source_ns": [
        56
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C57",
      "text": "Autopsy comparison showed prominent microvascular thrombosis and angiogenesis versus influenza. Small fatal-only series; ultrastructural virus identification and mechanism direction require independent verification.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4",
        "SC5"
      ],
      "source_ns": [
        57
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C58",
      "text": "Rising CRP during first48h predicted respiratory deterioration better than initial levels. Retrospective risk marker, no targeted causal or absolute cytokine-magnitude test.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        58
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C59",
      "text": "Fatal single-cell lung atlas linked cytokine-producing cells, immune dysfunction and failed alveolar repair. End-stage transcriptomic/interaction inference; linked erratum remains unaudited; not direct concentration or intervention evidence.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4",
        "SC5"
      ],
      "source_ns": [
        59
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C60",
      "text": "Activin/FLRG predicted poor outcomes; hamster blockade did not worsen viral load/pathology. No positive improved disease endpoint in the abstract; absence of worsening is not efficacy or driver proof.",
      "carries_number": false,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        60
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C61",
      "text": "Peripheral single-cell profiling described monocyte expansion, T-cell depletion and reduced antigen presentation. Peripheral descriptive states do not establish causal direction or systemic hypercytokinemia magnitude.",
      "carries_number": false,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        61
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C62",
      "text": "RIGI/MDA5 and downstream inhibition reduced infected epithelial-to-macrophage inflammatory signalling. Cultured primary-cell circuit, no in vivo necessity or compartment-specific mortality test.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC5"
      ],
      "source_ns": [
        62
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C63",
      "text": "IL13 neutralization reduced infected-mouse mortality without lowering virus; CD44 blockade narrowed HA mediation. Human dupilumab observations confounded; IL13/HA is not an IL6/IL1 clinical test nor systemic-storm magnitude proof.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4",
        "SC5"
      ],
      "source_ns": [
        63
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C64",
      "text": "IL1beta loss improved infected-mouse disease/survival while several inflammasome/pyroptosis deletions did not. Germline developmental and mouse-adapted-virus scope; cytokine causality does not establish the presumed release pathway.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC4"
      ],
      "source_ns": [
        64
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C65",
      "text": "SARSCoV2 induced epithelial complement and JAK1/2 inhibition normalized selected genes/C3a. Expression and cell inhibition do not establish human necessity, efficacy or dominant systemic lesion.",
      "carries_number": true,
      "load_bearing_for": [
        "SC3",
        "SC5"
      ],
      "source_ns": [
        65
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C66",
      "text": "BAL transcriptomes in eight cases showed inflammatory and IFN-stimulated signatures. RNA is not secreted cytokine concentration; small disease-stage sampling; no causal compartment test.",
      "carries_number": false,
      "load_bearing_for": [
        "SC5"
      ],
      "source_ns": [
        66
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C67",
      "text": "Four early-intubated cases showed lung and blood hyperinflammation, particularly lung IL8. Raw BAL values were diluted; blood and BAL not universally discordant; selection and small sample limit generalization.",
      "carries_number": true,
      "load_bearing_for": [
        "SC5",
        "SC4"
      ],
      "source_ns": [
        67
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph13, 1:Results:paragraph22, 2:Discussion:paragraph4, 2:Discussion:paragraph7, 2:Discussion:paragraph8, 0:Methods:paragraph0, 0:Methods:paragraph1, 0:Methods:paragraph2, 0:Methods:paragraph3, 0:Methods:paragraph4, 0:Methods:paragraph5, 0:Methods:paragraph6. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "C68",
      "text": "Only7 of168 COVID patients had storm-like profiles; adjusted cytokines were lower than influenza and IFN signatures suppressed. Relative storm definition and observational sampling; shared comparative research network does not ensure all cohorts independent.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC4"
      ],
      "source_ns": [
        68
      ],
      "verification": "verified",
      "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "CSC1",
      "text": "Circulating IL6 and related markers predict deterioration and survival, including temporal validation [3-7,58]. This is a strong prognostic observation, not causal primacy.",
      "carries_number": false,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        3,
        4,
        5,
        6,
        7,
        10,
        28,
        58,
        60,
        61
      ],
      "verification": "verified",
      "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "CSC2",
      "text": "Direct comparative observations are heterogeneous. The same-method ICU comparison and influenza comparison constrain general storm magnitude [1,68]; the small MFI-panel null [2] is not equivalence. The registered magnitude claim is not established across its scope.",
      "carries_number": false,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        1,
        2,
        8,
        9,
        54,
        68
      ],
      "verification": "verified",
      "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "CSC3",
      "text": "IL6R-targeted mortality/organ-support benefits in separate RECOVERY and REMAP-CAP populations, placebo-controlled composite benefit in EMPACTA, and mechanistically different IL1 perturbation in SAVE-MORE reduce a purely passive-inflammatory-marker interpretation [13-15,18]. IL6R blockade is one causal line under the framework's independence test (agents of the same modality against the same target do not count twice, and replication adds confidence rather than a line); Ζ rests on its convergence with the mechanistically distinct IL1 blockade result and the infected-model IL1beta genetic contrast. IL1 clinical contribution is more selection-sensitive and bounded at Ε. Nulls identify boundaries rather than erasing all causal contribution [16-26,29-30].",
      "carries_number": false,
      "load_bearing_for": [
        "SC3"
      ],
      "source_ns": [
        13,
        14,
        15,
        16,
        17,
        18,
        19,
        20,
        21,
        22,
        23,
        24,
        25,
        26,
        27,
        28,
        29,
        30,
        31,
        33,
        34,
        35,
        36,
        40,
        62,
        64,
        65
      ],
      "verification": "verified",
      "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "CSC4",
      "text": "Positive pathway-specific trials establish contribution, but cannot identify circulating magnitude or the fraction of disease primarily caused by that state. Host IFN natural experiments, antiviral benefit, vascular injury and compartment data make systemic-storm primacy mechanistically unestablished [32,37-50,54-57,68].",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        1,
        2,
        3,
        4,
        5,
        7,
        8,
        9,
        10,
        11,
        12,
        13,
        14,
        16,
        17,
        18,
        19,
        20,
        24,
        25,
        26,
        27,
        29,
        30,
        31,
        32,
        33,
        34,
        35,
        36,
        37,
        38,
        39,
        40,
        41,
        42,
        43,
        44,
        45,
        46,
        47,
        48,
        49,
        50,
        51,
        52,
        53,
        55,
        56,
        57,
        59,
        60,
        61,
        63,
        64,
        67,
        68
      ],
      "verification": "verified",
      "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "CSC5",
      "text": "Systemic drug delivery does not localize pathogenic action. Paired blood/lung measurements show mediator-specific compartment relations and treatment effects, not proof that the disease-driving cytokine action is primarily systemic [11,51-54,65-67].",
      "carries_number": false,
      "load_bearing_for": [
        "SC5"
      ],
      "source_ns": [
        11,
        51,
        52,
        53,
        54,
        55,
        56,
        57,
        59,
        62,
        63,
        65,
        66,
        67
      ],
      "verification": "verified",
      "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.",
      "verified_on": "2026-10-05",
      "note": ""
    },
    {
      "id": "CH",
      "text": "Targeted cytokine signalling contributes causally in selected hospitalized COVID-19 populations. The evidence does not establish sepsis-like systemic hypercytokinemia as the primary cause of severe disease and mortality.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        13,
        14,
        18,
        1,
        2,
        44
      ],
      "verification": "verified",
      "verified_against": "Bounded synthesis of examined sources; score is adjudication.",
      "verified_on": "2026-10-05",
      "note": ""
    }
  ],
  "citation_ledger": [
    {
      "n": 1,
      "citation": "Kox M, Waalders NJB, Kooistra EJ et al. Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions. JAMA. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32880615",
      "doi": "10.1001/jama.2020.17052",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32880615/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32880615",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: Publisher Methods, Results and Discussion, displayed lines 141-196; summary receipt. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C1",
        "CSC2",
        "CSC4",
        "CH"
      ]
    },
    {
      "n": 2,
      "citation": "Wilson JG, Simpson LJ, Ferreira AM et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI insight. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32706339",
      "doi": "10.1172/jci.insight.140289",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32706339/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32706339",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph1, 1:Results:paragraph2, 1:Results:paragraph3, 2:Discussion:paragraph0, 2:Discussion:paragraph1, 2:Discussion:paragraph3, 2:Discussion:paragraph4, 3:Methods:paragraph1, 3:Methods:paragraph2, 3:Methods:paragraph3, 3:Methods:paragraph4, 3:Methods:paragraph5. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C2",
        "CSC2",
        "CSC4",
        "CH"
      ]
    },
    {
      "n": 3,
      "citation": "Bülow Anderberg S, Luther T, Berglund M et al. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33348065",
      "doi": "10.1016/j.cyto.2020.155389",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33348065/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33348065",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C3",
        "CSC1",
        "CSC4"
      ]
    },
    {
      "n": 4,
      "citation": "Dorgham K, Quentric P, Gökkaya M et al. Distinct cytokine profiles associated with COVID-19 severity and mortality. The Journal of allergy and clinical immunology. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33894209",
      "doi": "10.1016/j.jaci.2021.03.047",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33894209/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33894209",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C4",
        "CSC1",
        "CSC4"
      ]
    },
    {
      "n": 5,
      "citation": "Del Valle DM, Kim-Schulze S, Huang HH et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature medicine. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32839624",
      "doi": "10.1038/s41591-020-1051-9",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32839624/",
      "status_flags": [
        "UpdateOf: PMID32511562"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32839624",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C5",
        "CSC1",
        "CSC4"
      ]
    },
    {
      "n": 6,
      "citation": "Herold T, Jurinovic V, Arnreich C et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. The Journal of allergy and clinical immunology. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32425269",
      "doi": "10.1016/j.jaci.2020.05.008",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32425269/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32425269",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C6",
        "CSC1"
      ]
    },
    {
      "n": 7,
      "citation": "Lucas C, Wong P, Klein J et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32717743",
      "doi": "10.1038/s41586-020-2588-y",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32717743/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32717743",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C7",
        "CSC1",
        "CSC4"
      ]
    },
    {
      "n": 8,
      "citation": "Remy KE, Mazer M, Striker DA et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI insight. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32687484",
      "doi": "10.1172/jci.insight.140329",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32687484/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32687484",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C8",
        "CSC2",
        "CSC4"
      ]
    },
    {
      "n": 9,
      "citation": "Loftus TJ, Ungaro R, Dirain M et al. Overlapping but Disparate Inflammatory and Immunosuppressive Responses to SARS-CoV-2 and Bacterial Sepsis: An Immunological Time Course Analysis. Frontiers in immunology. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "34956225",
      "doi": "10.3389/fimmu.2021.792448",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34956225/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34956225",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C9",
        "CSC2",
        "CSC4"
      ]
    },
    {
      "n": 10,
      "citation": "Janssen NAF, Grondman I, de Nooijer AH et al. Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. The Journal of infectious diseases. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33524124",
      "doi": "10.1093/infdis/jiab065",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33524124/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33524124",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C10",
        "CSC1",
        "CSC4"
      ]
    },
    {
      "n": 11,
      "citation": "Reynolds D, Vazquez Guillamet C, Day A et al. Comprehensive Immunologic Evaluation of Bronchoalveolar Lavage Samples from Human Patients with Moderate and Severe Seasonal Influenza and Severe COVID-19. Journal of immunology (Baltimore, Md. : 1950). 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "34348975",
      "doi": "10.4049/jimmunol.2100294",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34348975/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34348975",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C11",
        "CSC4",
        "CSC5"
      ]
    },
    {
      "n": 12,
      "citation": "Kreutmair S, Unger S, Núñez NG et al. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. Immunity. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "34051147",
      "doi": "10.1016/j.immuni.2021.05.002",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34051147/",
      "status_flags": [
        "ErratumIn: PMID35139354"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34051147",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C12",
        "CSC4"
      ]
    },
    {
      "n": 13,
      "citation": "  et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England). 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "33933206",
      "doi": "10.1016/S0140-6736(21)00676-0",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33933206/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33933206",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph6, 1:Methods:paragraph7, 1:Methods:paragraph8, 1:Methods:paragraph9, 1:Methods:paragraph11, 1:Methods:paragraph12, 2:Results:paragraph0, 2:Results:paragraph2, 2:Results:paragraph9, 2:Results:paragraph10, 2:Results:paragraph11, 2:Results:paragraph13, 2:Results:paragraph14, 2:Results:paragraph15, 2:Results:paragraph16. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C13",
        "CSC3",
        "CSC4",
        "CH"
      ]
    },
    {
      "n": 14,
      "citation": " , Gordon AC, Mouncey PR et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The New England journal of medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "33631065",
      "doi": "10.1056/NEJMoa2100433",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33631065/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "REMAP-CAP-IL6-domain-2020-2021",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C14",
        "CSC3",
        "CSC4",
        "CH"
      ]
    },
    {
      "n": 15,
      "citation": "Salama C, Han J, Yau L et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. The New England journal of medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "33332779",
      "doi": "10.1056/NEJMoa2030340",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33332779/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33332779",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C15",
        "CSC3"
      ]
    },
    {
      "n": 16,
      "citation": "Rosas IO, Bräu N, Waters M et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. The New England journal of medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "33631066",
      "doi": "10.1056/NEJMoa2028700",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33631066/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "COVACTA-NCT04320615",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C16",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 17,
      "citation": "Stone JH, Frigault MJ, Serling-Boyd NJ et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. The New England journal of medicine. 2020.",
      "tier": "A",
      "kind": "rct",
      "pmid": "33085857",
      "doi": "10.1056/NEJMoa2028836",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33085857/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33085857",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C17",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 18,
      "citation": "Kyriazopoulou E, Poulakou G, Milionis H et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "34480127",
      "doi": "10.1038/s41591-021-01499-z",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34480127/",
      "status_flags": [
        "ErratumIn: PMID34625750"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "SAVE-MORE-NCT04680949",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph6, 1:Results:paragraph7, 1:Results:paragraph8, 1:Results:paragraph12, 1:Results:paragraph14, 1:Results:paragraph15, 2:Discussion:paragraph5, 2:Discussion:paragraph6, 3:Methods:paragraph0, 3:Methods:paragraph2, 3:Methods:paragraph3, 3:Methods:paragraph4, 3:Methods:paragraph6, 3:Methods:paragraph7. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C18",
        "CSC3",
        "CSC4",
        "CH"
      ]
    },
    {
      "n": 19,
      "citation": "  et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. The Lancet. Respiratory medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "33493450",
      "doi": "10.1016/S2213-2600(20)30556-7",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33493450/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33493450",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C19",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 20,
      "citation": "Caricchio R, Abbate A, Gordeev I et al. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "34283183",
      "doi": "10.1001/jama.2021.9508",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34283183/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34283183",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C20",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 21,
      "citation": "Lescure FX, Honda H, Fowler RA et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Respiratory medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "33676590",
      "doi": "10.1016/S2213-2600(21)00099-0",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33676590/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33676590",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C21",
        "CSC3"
      ]
    },
    {
      "n": 22,
      "citation": "Sivapalasingam S, Lederer DJ, Bhore R et al. Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022.",
      "tier": "A",
      "kind": "rct",
      "pmid": "35219277",
      "doi": "10.1093/cid/ciac153",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35219277/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35219277",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C22",
        "CSC3"
      ]
    },
    {
      "n": 23,
      "citation": "Merchante N, Cárcel S, Garrido-Gracia JC et al. Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial. Antimicrobial agents and chemotherapy. 2022.",
      "tier": "A",
      "kind": "rct",
      "pmid": "34902262",
      "doi": "10.1128/AAC.02107-21",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34902262/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34902262",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C23",
        "CSC3"
      ]
    },
    {
      "n": 24,
      "citation": "Fanlo P, Gracia-Tello BDC, Fonseca Aizpuru E et al. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial. JAMA network open. 2023.",
      "tier": "A",
      "kind": "rct",
      "pmid": "37027155",
      "doi": "10.1001/jamanetworkopen.2023.7243",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37027155/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID37027155",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C24",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 25,
      "citation": "Declercq J, Van Damme KFA, De Leeuw E et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. The Lancet. Respiratory medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "34756178",
      "doi": "10.1016/S2213-2600(21)00377-5",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34756178/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34756178",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C25",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 26,
      "citation": "Audemard-Verger A, Le Gouge A, Pestre V et al. Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial. PloS one. 2022.",
      "tier": "A",
      "kind": "rct",
      "pmid": "35925914",
      "doi": "10.1371/journal.pone.0269065",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35925914/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35925914",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C26",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 27,
      "citation": "Kyriazopoulou E, Hasin-Brumshtein Y, Midic U et al. Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial. Critical care (London, England). 2024.",
      "tier": "A",
      "kind": "rct",
      "pmid": "38475786",
      "doi": "10.1186/s13054-024-04852-z",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38475786/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "SAVE-MORE-NCT04680949",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C27",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 28,
      "citation": "Tom J, Bao M, Tsai L et al. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. Critical care medicine. 2022.",
      "tier": "A",
      "kind": "rct",
      "pmid": "34612846",
      "doi": "10.1097/CCM.0000000000005229",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34612846/",
      "status_flags": [
        "ErratumIn: PMID37439653"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "COVACTA-NCT04320615",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C28",
        "CSC1",
        "CSC3"
      ]
    },
    {
      "n": 29,
      "citation": "Rosas IO, Diaz G, Gottlieb RL et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive care medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "34609549",
      "doi": "10.1007/s00134-021-06507-x",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34609549/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34609549",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C29",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 30,
      "citation": "Derde L, Gordon AC, Mouncey PR et al. Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial. Thorax. 2025.",
      "tier": "A",
      "kind": "rct",
      "pmid": "40360262",
      "doi": "10.1136/thorax-2024-222488",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40360262/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "REMAP-CAP-IL6-domain-2020-2021",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C30",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 31,
      "citation": " , Horby P, Lim WS et al. Dexamethasone in Hospitalized Patients with Covid-19. The New England journal of medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "32678530",
      "doi": "10.1056/NEJMoa2021436",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32678530/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32678530",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C31",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 32,
      "citation": "Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 - Final Report. The New England journal of medicine. 2020.",
      "tier": "A",
      "kind": "rct",
      "pmid": "32445440",
      "doi": "10.1056/NEJMoa2007764",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32445440/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "ACTT1-NCT04280705",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C32",
        "CSC4"
      ]
    },
    {
      "n": 33,
      "citation": "Kalil AC, Patterson TF, Mehta AK et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. The New England journal of medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "33306283",
      "doi": "10.1056/NEJMoa2031994",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33306283/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33306283",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C33",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 34,
      "citation": "Marconi VC, Ramanan AV, de Bono S et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. The Lancet. Respiratory medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "34480861",
      "doi": "10.1016/S2213-2600(21)00331-3",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34480861/",
      "status_flags": [
        "ErratumIn: PMID34508656"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34480861",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph7, 1:Methods:paragraph8, 1:Methods:paragraph9, 1:Methods:paragraph10, 1:Methods:paragraph11, 2:Results:paragraph11, 2:Results:paragraph12, 2:Results:paragraph13, 2:Results:paragraph18, 2:Results:paragraph19, 2:Results:paragraph20, 2:Results:paragraph21. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C34",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 35,
      "citation": "  et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet (London, England). 2022.",
      "tier": "A",
      "kind": "primary",
      "pmid": "35908569",
      "doi": "10.1016/S0140-6736(22)01109-6",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35908569/",
      "status_flags": [
        "ErratumIn: PMID36183728"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35908569",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C35",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 36,
      "citation": " ,   et al. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England). 2023.",
      "tier": "A",
      "kind": "rct",
      "pmid": "37060915",
      "doi": "10.1016/S0140-6736(23)00510-X",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37060915/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID37060915",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C36",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 37,
      "citation": " ,  ,   et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. The New England journal of medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "34351722",
      "doi": "10.1056/NEJMoa2103417",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34351722/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34351722",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C37",
        "CSC4"
      ]
    },
    {
      "n": 38,
      "citation": " ,  ,   et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. The New England journal of medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "34351721",
      "doi": "10.1056/NEJMoa2105911",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34351721/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34351721",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C38",
        "CSC4"
      ]
    },
    {
      "n": 39,
      "citation": "Kalil AC, Mehta AK, Patterson TF et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. The Lancet. Respiratory medicine. 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "34672949",
      "doi": "10.1016/S2213-2600(21)00384-2",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34672949/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34672949",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C39",
        "CSC4"
      ]
    },
    {
      "n": 40,
      "citation": "Wolfe CR, Tomashek KM, Patterson TF et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. The Lancet. Respiratory medicine. 2022.",
      "tier": "A",
      "kind": "rct",
      "pmid": "35617986",
      "doi": "10.1016/S2213-2600(22)00088-1",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35617986/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35617986",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C40",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 41,
      "citation": "  et al. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. The Lancet. Respiratory medicine. 2022.",
      "tier": "A",
      "kind": "rct",
      "pmid": "35817072",
      "doi": "10.1016/S2213-2600(22)00215-6",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35817072/",
      "status_flags": [
        "ErratumIn: PMID36356600"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35817072",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C41",
        "CSC4"
      ]
    },
    {
      "n": 42,
      "citation": "Singh K, Rubenstein K, Callier V et al. SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. The Journal of infectious diseases. 2024.",
      "tier": "A",
      "kind": "rct",
      "pmid": "38657001",
      "doi": "10.1093/infdis/jiae198",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38657001/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "ACTT1-NCT04280705",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C42",
        "CSC4"
      ]
    },
    {
      "n": 43,
      "citation": "Bastard P, Rosen LB, Zhang Q et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (New York, N.Y.). 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32972996",
      "doi": "10.1126/science.abd4585",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32972996/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "IFN-autoAb-initial-overlaps-extension",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C43",
        "CSC4"
      ]
    },
    {
      "n": 44,
      "citation": "Zhang Q, Bastard P, Liu Z et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science (New York, N.Y.). 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32972995",
      "doi": "10.1126/science.abd4570",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32972995/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32972995",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C44",
        "CSC4",
        "CH"
      ]
    },
    {
      "n": 45,
      "citation": "Bastard P, Gervais A, Le Voyer T et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science immunology. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "34413139",
      "doi": "10.1126/sciimmunol.abl4340",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34413139/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "IFN-autoAb-extension-includes-initial",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph0, 1:RESULTS:paragraph1, 1:RESULTS:paragraph2, 1:RESULTS:paragraph3, 1:RESULTS:paragraph4, 1:RESULTS:paragraph5, 1:RESULTS:paragraph6. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C45",
        "CSC4"
      ]
    },
    {
      "n": 46,
      "citation": "Manry J, Bastard P, Gervais A et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America. 2022.",
      "tier": "A",
      "kind": "primary",
      "pmid": "35576468",
      "doi": "10.1073/pnas.2200413119",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35576468/",
      "status_flags": [
        "UpdateOf: PMID35043109"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "IFN-fatality-shared34159-controls",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C46",
        "CSC4"
      ]
    },
    {
      "n": 47,
      "citation": "Zhang Q, Matuozzo D, Le Pen J et al. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. The Journal of experimental medicine. 2022.",
      "tier": "A",
      "kind": "primary",
      "pmid": "35708626",
      "doi": "10.1084/jem.20220131",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35708626/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID35708626",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C47",
        "CSC4"
      ]
    },
    {
      "n": 48,
      "citation": "García-García A, Pérez de Diego R, Flores C et al. Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia. The Journal of experimental medicine. 2023.",
      "tier": "A",
      "kind": "primary",
      "pmid": "36880831",
      "doi": "10.1084/jem.20220170",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36880831/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID36880831",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C48",
        "CSC4"
      ]
    },
    {
      "n": 49,
      "citation": "Matuozzo D, Talouarn E, Marchal A et al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome medicine. 2023.",
      "tier": "A",
      "kind": "primary",
      "pmid": "37020259",
      "doi": "10.1186/s13073-023-01173-8",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37020259/",
      "status_flags": [
        "UpdateOf: PMID36324795",
        "ErratumIn: PMID38184654"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID37020259",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C49",
        "CSC4"
      ]
    },
    {
      "n": 50,
      "citation": "Antolí A, Gómez-Vázquez JL, Sierra-Fortuny A et al. Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients. Clinical immunology (Orlando, Fla.). 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "40185298",
      "doi": "10.1016/j.clim.2025.110491",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40185298/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID40185298",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C50",
        "CSC4"
      ]
    },
    {
      "n": 51,
      "citation": "Ouwendijk WJD, Raadsen MP, van Kampen JJA et al. High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019. The Journal of infectious diseases. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33507309",
      "doi": "10.1093/infdis/jiab050",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33507309/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33507309",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C51",
        "CSC4",
        "CSC5"
      ]
    },
    {
      "n": 52,
      "citation": "Carvelli J, Demaria O, Vély F et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32726800",
      "doi": "10.1038/s41586-020-2600-6",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32726800/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32726800",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C52",
        "CSC4",
        "CSC5"
      ]
    },
    {
      "n": 53,
      "citation": "Toldo S, Bussani R, Nuzzi V et al. Inflammasome formation in the lungs of patients with fatal COVID-19. Inflammation research : official journal of the European Histamine Research Society ... [et al.]. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33079210",
      "doi": "10.1007/s00011-020-01413-2",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33079210/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33079210",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C53",
        "CSC4",
        "CSC5"
      ]
    },
    {
      "n": 54,
      "citation": "Jonassen TB, Jørgensen SE, Mitchell NH et al. Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS. Frontiers in immunology. 2024.",
      "tier": "A",
      "kind": "primary",
      "pmid": "38571960",
      "doi": "10.3389/fimmu.2024.1353012",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38571960/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "Hvidovre-CARDS-overlap-with2021-unresolved",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph5, 1:Methods:paragraph6, 1:Methods:paragraph7, 2:Results:paragraph0, 2:Results:paragraph2, 2:Results:paragraph9, 2:Results:paragraph10, 2:Results:paragraph13, 2:Results:paragraph14, 2:Results:paragraph15, 2:Results:paragraph16, 2:Results:paragraph17. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C54",
        "CSC2",
        "CSC5"
      ]
    },
    {
      "n": 55,
      "citation": "Ryu JK, Yan Z, Montano M et al. Fibrin drives thromboinflammation and neuropathology in COVID-19. Nature. 2024.",
      "tier": "A",
      "kind": "primary",
      "pmid": "39198643",
      "doi": "10.1038/s41586-024-07873-4",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39198643/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID39198643",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C55",
        "CSC4",
        "CSC5"
      ]
    },
    {
      "n": 56,
      "citation": "Delorey TM, Ziegler CGK, Heimberg G et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33915569",
      "doi": "10.1038/s41586-021-03570-8",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33915569/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33915569",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C56",
        "CSC4",
        "CSC5"
      ]
    },
    {
      "n": 57,
      "citation": "Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. The New England journal of medicine. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32437596",
      "doi": "10.1056/NEJMoa2015432",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32437596/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32437596",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C57",
        "CSC4",
        "CSC5"
      ]
    },
    {
      "n": 58,
      "citation": "Mueller AA, Tamura T, Crowley CP et al. Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients. Cell reports. Medicine. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33163981",
      "doi": "10.1016/j.xcrm.2020.100144",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33163981/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33163981",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C58",
        "CSC1"
      ]
    },
    {
      "n": 59,
      "citation": "Melms JC, Biermann J, Huang H et al. A molecular single-cell lung atlas of lethal COVID-19. Nature. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33915568",
      "doi": "10.1038/s41586-021-03569-1",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33915568/",
      "status_flags": [
        "ErratumIn: PMID34625743"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33915568",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C59",
        "CSC4",
        "CSC5"
      ]
    },
    {
      "n": 60,
      "citation": "McAleavy M, Zhang Q, Ehmann PJ et al. The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients. Molecular and cellular biology. 2022.",
      "tier": "A",
      "kind": "rct",
      "pmid": "34723652",
      "doi": "10.1128/MCB.00467-21",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34723652/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34723652",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C60",
        "CSC1",
        "CSC4"
      ]
    },
    {
      "n": 61,
      "citation": "Shi W, Liu X, Cao Q et al. High-dimensional single-cell analysis reveals the immune characteristics of COVID-19. American journal of physiology. Lung cellular and molecular physiology. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33146564",
      "doi": "10.1152/ajplung.00355.2020",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33146564/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33146564",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C61",
        "CSC1",
        "CSC4"
      ]
    },
    {
      "n": 62,
      "citation": "Thorne LG, Reuschl AK, Zuliani-Alvarez L et al. SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. The EMBO journal. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "34101213",
      "doi": "10.15252/embj.2021107826",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34101213/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34101213",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C62",
        "CSC3",
        "CSC5"
      ]
    },
    {
      "n": 63,
      "citation": "Donlan AN, Sutherland TE, Marie C et al. IL-13 is a driver of COVID-19 severity. JCI insight. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "34185704",
      "doi": "10.1172/jci.insight.150107",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34185704/",
      "status_flags": [
        "UpdateOf: PMID33688686"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID34185704",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C63",
        "CSC4",
        "CSC5"
      ]
    },
    {
      "n": 64,
      "citation": "M Bader S, Scherer L, Schaefer J et al. IL-1β drives SARS-CoV-2-induced disease independently of the inflammasome and pyroptosis signalling. Cell death and differentiation. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "40016339",
      "doi": "10.1038/s41418-025-01459-x",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40016339/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID40016339",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C64",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 65,
      "citation": "Yan B, Freiwald T, Chauss D et al. SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Science immunology. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33827897",
      "doi": "10.1126/sciimmunol.abg0833",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33827897/",
      "status_flags": [
        "UpdateOf: PMID32702726"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33827897",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C65",
        "CSC3",
        "CSC5"
      ]
    },
    {
      "n": 66,
      "citation": "Zhou Z, Ren L, Zhang L et al. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell host & microbe. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32407669",
      "doi": "10.1016/j.chom.2020.04.017",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32407669/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID32407669",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C66",
        "CSC5"
      ]
    },
    {
      "n": 67,
      "citation": "Ronit A, Berg RMG, Bay JT et al. Compartmental immunophenotyping in COVID-19 ARDS: A case series. The Journal of allergy and clinical immunology. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32979342",
      "doi": "10.1016/j.jaci.2020.09.009",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32979342/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "Hvidovre-CARDS-overlap-with2024-unresolved",
      "access_depth": "full_text_partial",
      "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph13, 1:Results:paragraph22, 2:Discussion:paragraph4, 2:Discussion:paragraph7, 2:Discussion:paragraph8, 0:Methods:paragraph0, 0:Methods:paragraph1, 0:Methods:paragraph2, 0:Methods:paragraph3, 0:Methods:paragraph4, 0:Methods:paragraph5, 0:Methods:paragraph6. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C67",
        "CSC4",
        "CSC5"
      ]
    },
    {
      "n": 68,
      "citation": "Mudd PA, Crawford JC, Turner JS et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Science advances. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33187979",
      "doi": "10.1126/sciadv.abe3024",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33187979/",
      "status_flags": [
        "UpdateOf: PMID32511543"
      ],
      "opened": true,
      "opened_on": "2026-10-05",
      "status_checked_on": "2026-10-05",
      "study_id": "PMID33187979",
      "access_depth": "abstract_metadata",
      "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C68",
        "CSC2",
        "CSC4"
      ]
    }
  ],
  "independence_basis": {
    "required": true,
    "lines": [
      {
        "label": "Target-specific clinical perturbation",
        "sources": [
          13,
          14,
          15,
          18
        ],
        "excludes_error": "Randomization reduces severity-driven prescribing; placebo-controlled EMPACTA/SAVE-MORE reduce open-label management bias. Distinct targets weaken a single off-target explanation, but eligibility and outcomes differ."
      },
      {
        "label": "Temporally prior human IFN natural experiments (rival model; not counted toward SC3)",
        "sources": [
          44,
          43,
          45,
          47,
          48
        ],
        "excludes_error": "Inherited defects and documented preinfection autoantibodies reduce reverse causation; functional neutralization/infection tests reduce a binding-marker-only explanation. Recruitment and cohort overlap remain."
      },
      {
        "label": "Mediator and pathway contrasts in infected models",
        "sources": [
          63,
          64,
          55
        ],
        "excludes_error": "Orthogonal mediator/domain manipulations separate inflammatory contribution from blood association and from assumed processing routes, with model/developmental limits."
      }
    ],
    "shared_failure_mode_checked": true,
    "note": "Ζ SC3 rests on randomized targeted effects, placebo controls and orthogonal mechanistic support that address different errors, not the number of papers or sites. The IFN natural-experiment line is recorded because it bears on the rival susceptibility model; it is not counted toward the SC3 convergence. RECOVERY arms share a platform/co-randomization; REMAP-CAP2021/2025, SAVE-MORE primary/substudy, COVACTA primary/biomarkers and ACTT1 primary/virology are report families. The IFN-autoantibody extension includes566 original critical patients and427 controls; fatality estimation reuses the34159 population controls. The IFN rival combines temporally prior genetic and autoimmune causes with functional assays rather than counting those overlapping reports separately."
  },
  "consensus_validation": {
    "completed": true,
    "status": "documented_historical_discovery_and_reconciliation",
    "provider": "Consensus",
    "provider_mode": "Historical browser/connector use as recorded in the source artifacts",
    "local_audit_date": "2026-10-09",
    "primary_comparison_count": null,
    "reported_usage": [],
    "grade_changed": false,
    "score_before": {
      "hsef_level": "Γ",
      "hsef_descriptor": "Mechanistically plausible, partial system support",
      "confidence": "Moderate",
      "confidence_rationale": "68 primary reports with 8 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
      "rests_on_non_peer_reviewed_work": false,
      "rationale": "The preregistered scope-matched gate SC4 yields Γ / Moderate for systemic-storm primacy. SC3 earns Ζ for convergent targeted cytokine contribution in prespecified hospitalized contexts; this is explicitly retained. Weakest-link sensitivity is Β because SC1/SC2 are descriptive observations. Primary-subclaim and scope-matched sensitivities are Γ. Treatable inflammation and a cytokine-first systemic magnitude claim are different propositions."
    },
    "score_after": {
      "hsef_level": "Γ",
      "hsef_descriptor": "Mechanistically plausible, partial system support",
      "confidence": "Moderate",
      "confidence_rationale": "68 primary reports with 8 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
      "rests_on_non_peer_reviewed_work": false,
      "rationale": "The preregistered scope-matched gate SC4 yields Γ / Moderate for systemic-storm primacy. SC3 earns Ζ for convergent targeted cytokine contribution in prespecified hospitalized contexts; this is explicitly retained. Weakest-link sensitivity is Β because SC1/SC2 are descriptive observations. Primary-subclaim and scope-matched sensitivities are Γ. Treatable inflammation and a cytokine-first systemic magnitude claim are different propositions."
    },
    "independent_blinded_audit": false,
    "raw_receipts": [
      {
        "path": "deliverables\\hsef_v53_popularity_ranks_06_10_2026-10-05\\cytokine-storm-covid-driver\\consensus\\consensus-result.png",
        "sha256": "e5c270fcd567bdf77c17f552ee87ed49f488cb0ca3d0e1a0887f425ae053199d"
      },
      {
        "path": "deliverables\\hsef_v53_popularity_ranks_06_10_2026-10-05\\cytokine-storm-covid-driver\\consensus\\deep-dom.txt",
        "sha256": "1041e319c5136e3e365faa8315503fa10e921117ffe98d588c7f3cf9f9620382"
      },
      {
        "path": "deliverables\\hsef_v53_popularity_ranks_06_10_2026-10-05\\cytokine-storm-covid-driver\\consensus\\deep-response.txt",
        "sha256": "ca3390947994eafb42ad04acc498edc5304512e730f21e439d6ab5d9559c8ddf"
      },
      {
        "path": "deliverables\\hsef_v53_popularity_ranks_06_10_2026-10-05\\cytokine-storm-covid-driver\\consensus\\final-dom.txt",
        "sha256": "c9665683c6c7beaf45307570f0e0cb2ba1169142528ee8b4e621181bf4038ec4"
      },
      {
        "path": "deliverables\\hsef_v53_popularity_ranks_06_10_2026-10-05\\cytokine-storm-covid-driver\\consensus\\fulltext-check-response.txt",
        "sha256": "e43a1b21246502c8e1bc736c055ae58c8035780d146736a2bbd595ec4a2cc1f0"
      }
    ],
    "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record."
  }
}